US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
ES2434961T5
(es)
*
|
1998-04-20 |
2018-01-18 |
Roche Glycart Ag |
Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
|
EP2264177B1
(en)
|
1998-12-09 |
2015-09-30 |
Phyton Holdings, LLC |
Glycoproteins having human-type glycosylation
|
ATE464907T1
(de)
|
1999-02-17 |
2010-05-15 |
Csl Ltd |
Immunogene komplexe und methoden in bezug auf diese
|
DE60035285T2
(de)
|
1999-10-26 |
2008-02-21 |
Plant Research International B.V. |
Glykolisierung des säugetiertyps in pflanzen
|
AU5345901A
(en)
*
|
2000-04-13 |
2001-10-30 |
Univ Rockefeller |
Enhancement of antibody-mediated immune responses
|
US7449308B2
(en)
*
|
2000-06-28 |
2008-11-11 |
Glycofi, Inc. |
Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
|
US8697394B2
(en)
*
|
2000-06-28 |
2014-04-15 |
Glycofi, Inc. |
Production of modified glycoproteins having multiple antennary structures
|
NZ523476A
(en)
*
|
2000-06-28 |
2004-04-30 |
Glycofi Inc |
Methods for humanizing glycosylation of recombinant glycoproteins expressed in lower eukaryotes
|
US7598055B2
(en)
*
|
2000-06-28 |
2009-10-06 |
Glycofi, Inc. |
N-acetylglucosaminyltransferase III expression in lower eukaryotes
|
CA2434364C
(en)
|
2001-01-19 |
2013-03-19 |
The Dow Chemical Company |
Method for secretory production of glycoprotein having human-type sugar chain using plant cell
|
AU2002307037B2
(en)
*
|
2001-04-02 |
2008-08-07 |
Biogen Idec Inc. |
Recombinant antibodies coexpressed with GnTIII
|
NZ581474A
(en)
|
2001-08-03 |
2011-04-29 |
Glycart Biotechnology Ag |
Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
|
EP1467755A1
(en)
*
|
2001-12-21 |
2004-10-20 |
Antigenics Inc. |
Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
|
US7662925B2
(en)
*
|
2002-03-01 |
2010-02-16 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
KR101228276B1
(ko)
|
2002-03-19 |
2013-01-30 |
스티칭 디엔스트 랜드보위쿤디그 온데조에크 |
식물에서 글리칸 프로세싱의 최적화
|
EP2319935B1
(en)
|
2002-03-19 |
2016-04-27 |
Stichting Dienst Landbouwkundig Onderzoek |
GnTIII (UDP-N-acetylglucosamine:Beta -D mannoside Beta (1,4)-N-acetylglucosaminyltransferase III) expression in plants.
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
AR042145A1
(es)
|
2002-11-27 |
2005-06-08 |
Dow Agrociences Llc |
Produccion de inmunoglobulinas en plantas con una fucocilacion reducida
|
CA2514058C
(en)
*
|
2003-01-24 |
2014-05-13 |
Agensys, Inc. |
Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer
|
US7332299B2
(en)
|
2003-02-20 |
2008-02-19 |
Glycofi, Inc. |
Endomannosidases in the modification of glycoproteins in eukaryotes
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
*
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20070275460A1
(en)
*
|
2003-03-03 |
2007-11-29 |
Xencor.Inc. |
Fc Variants With Optimized Fc Receptor Binding Properties
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
AR044388A1
(es)
|
2003-05-20 |
2005-09-07 |
Applied Molecular Evolution |
Moleculas de union a cd20
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
ME03330B
(me)
*
|
2003-11-05 |
2019-10-20 |
Roche Glycart Ag |
Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom
|
EP1697520A2
(en)
*
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
CA2555820C
(en)
|
2004-02-19 |
2016-01-19 |
Genentech, Inc. |
Cdr-repaired antibodies
|
AR048098A1
(es)
*
|
2004-03-15 |
2006-03-29 |
Wyeth Corp |
Conjugados de caliqueamicina
|
WO2005092925A2
(en)
*
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
AR049021A1
(es)
*
|
2004-04-16 |
2006-06-21 |
Genentech Inc |
Tratamiento de trastornos con un anticuerpo que se une a cd20
|
KR20130099228A
(ko)
|
2004-06-04 |
2013-09-05 |
제넨테크, 인크. |
다발성 경화증의 치료 방법
|
US7919086B2
(en)
*
|
2004-07-09 |
2011-04-05 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-glypican 3 antibody
|
WO2006005367A1
(en)
*
|
2004-07-14 |
2006-01-19 |
Igeneon Krebs-Immuntherapie Forschungs-Und Entwicklungs-Ag |
N-glycosylated antibody
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
US20060074225A1
(en)
*
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
AU2005294666A1
(en)
|
2004-10-05 |
2006-04-20 |
Genentech, Inc. |
Method for treating vasculitis
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
MX2007004593A
(es)
*
|
2004-10-26 |
2007-06-22 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-glipican 3 que tiene cadena de azucar modificada.
|
EP1817340B1
(en)
|
2004-11-12 |
2012-05-16 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
US20060275282A1
(en)
*
|
2005-01-12 |
2006-12-07 |
Xencor, Inc. |
Antibodies and Fc fusion proteins with altered immunogenicity
|
TWI441646B
(zh)
|
2005-01-21 |
2014-06-21 |
Genentech Inc |
帕妥珠單抗(pertuzumab)用於製備治療人類病患癌症之藥物的用途
|
EP1871805B1
(en)
*
|
2005-02-07 |
2019-09-25 |
Roche Glycart AG |
Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof
|
BRPI0607203A2
(pt)
*
|
2005-02-18 |
2009-08-25 |
Medarex Inc |
anticorpo anti-cd30 isolado, célula hospedeira, métodos para inibir o crescimento de células cd30+, e, uso de um anticorpo anti-cd30 desfucosilado
|
CN101163503B
(zh)
|
2005-02-23 |
2013-05-08 |
健泰科生物技术公司 |
使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
|
WO2006100582A1
(en)
*
|
2005-03-25 |
2006-09-28 |
Glycart Biotechnology Ag |
Antigen binding molecules directed to mcsp and having increased fc receptor binding affinity and effector function
|
PA8672101A1
(es)
|
2005-04-29 |
2006-12-07 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, métodos y usos
|
AU2006298519A1
(en)
*
|
2005-05-09 |
2007-04-12 |
Glycart Biotechnology Ag |
Antigen binding molecules having modified Fc regions and altered binding to Fc receptors
|
US20110129412A1
(en)
*
|
2005-06-02 |
2011-06-02 |
Astrazeneca Ab |
Antibodies Directed to CD20 and Uses Thereof
|
AU2006255085A1
(en)
*
|
2005-06-03 |
2006-12-14 |
Genentech, Inc. |
Method of producing antibodies with modified fucosylation level
|
LT2452694T
(lt)
|
2005-06-30 |
2019-02-25 |
Janssen Biotech, Inc. |
Anti-il-23 antikūnai, kompozicijos, būdai ir panaudojimai
|
CA2615846A1
(en)
|
2005-07-21 |
2007-01-25 |
Genmab A/S |
Potency assays for antibody drug substance binding to an fc receptor
|
US20070041979A1
(en)
*
|
2005-08-19 |
2007-02-22 |
Raju T S |
Proteolysis resistant antibody preparations
|
SG192479A1
(en)
*
|
2005-08-26 |
2013-08-30 |
Roche Glycart Ag |
Modified antigen binding molecules with altered cell signaling activity
|
WO2007041635A2
(en)
*
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
EP1951757B1
(en)
|
2005-10-06 |
2014-05-14 |
Xencor, Inc. |
Optimized anti-cd30 antibodies
|
US20070087005A1
(en)
|
2005-10-14 |
2007-04-19 |
Lazar Gregory A |
Anti-glypican-3 antibody
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
EP1954719A2
(en)
|
2005-12-02 |
2008-08-13 |
Genentech Inc. |
Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
|
DK3219328T3
(da)
|
2005-12-29 |
2020-07-13 |
Janssen Biotech Inc |
Humane anti-il-23-antistoffer, sammensætninger, fremgangsmåder og anvendelser
|
EP1973950B1
(en)
|
2006-01-05 |
2014-09-17 |
Genentech, Inc. |
Anti-ephb4 antibodies and methods using the same
|
AU2007205935B2
(en)
|
2006-01-17 |
2013-07-11 |
Synthon Biopharmaceuticals B.V. |
Compositions and methods for humanization and optimization of N-glycans in plants
|
US20070166306A1
(en)
*
|
2006-01-17 |
2007-07-19 |
Fey Georg H M |
Anti-CD19 antibody composition and method
|
JP2009528988A
(ja)
|
2006-02-10 |
2009-08-13 |
ライフ テクノロジーズ コーポレーション |
翻訳後修飾されたタンパク質の標識及び検出方法
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
CA2646329C
(en)
|
2006-03-20 |
2018-07-03 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
SG172656A1
(en)
|
2006-05-30 |
2011-07-28 |
Genentech Inc |
Antibodies and immunoconjugates and uses therefor
|
MX2008015541A
(es)
|
2006-06-06 |
2008-12-18 |
Genentech Inc |
Anticuerpos anti-dll4 y metodos que los usan.
|
RU2498999C2
(ru)
|
2006-07-14 |
2013-11-20 |
Ац Иммуне Са |
Гуманизированное антитело к амилоиду бета
|
KR20190003862A
(ko)
|
2006-07-14 |
2019-01-09 |
에이씨 이뮨 에스.에이. |
아밀로이드 베타에 대해 인간화된 항체
|
AU2007275654A1
(en)
|
2006-07-19 |
2008-01-24 |
The Trustees Of The University Of Pennsylvania |
WSX-1/p28 as a target for anti-inflammatory responses
|
AR062223A1
(es)
|
2006-08-09 |
2008-10-22 |
Glycart Biotechnology Ag |
Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
|
SI2383297T1
(sl)
|
2006-08-14 |
2013-06-28 |
Xencor Inc. |
Optimizirana antitelesa, ki ciljajo cd19
|
MY185872A
(en)
|
2006-09-13 |
2021-06-14 |
Abbvie Inc |
Cell culture improvements
|
US8911964B2
(en)
|
2006-09-13 |
2014-12-16 |
Abbvie Inc. |
Fed-batch method of making human anti-TNF-alpha antibody
|
JP5562031B2
(ja)
|
2006-09-18 |
2014-07-30 |
ゼンコー・インコーポレイテッド |
Hm1.24を標的とする最適化抗体
|
US7923011B2
(en)
*
|
2006-10-12 |
2011-04-12 |
Genentech, Inc. |
Antibodies to lymphotoxin-alpha
|
DK2845866T3
(en)
|
2006-10-27 |
2017-07-10 |
Genentech Inc |
Antibodies and immunoconjugates and their applications
|
MX2009005776A
(es)
|
2006-12-01 |
2009-06-10 |
Medarex Inc |
Anticuerpos humanos que se enlazan al cd 22 y sus usos.
|
US7834154B2
(en)
|
2007-02-09 |
2010-11-16 |
Genentech, Inc. |
Anti-ROBO4 antibodies and uses therefor
|
EP2899541A1
(en)
|
2007-03-02 |
2015-07-29 |
Genentech, Inc. |
Predicting response to a HER dimerisation inhbitor based on low HER3 expression
|
AU2008227024A1
(en)
*
|
2007-03-07 |
2008-09-18 |
Glycofi, Inc. |
Production of glycoproteins with modified fucosylation
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
CN101702919B
(zh)
|
2007-04-17 |
2014-08-13 |
基金会农业研究服务中心 |
植物通过表达非哺乳动物糖基转移酶而表现出哺乳动物类型的糖基化作用
|
AU2008255027B2
(en)
|
2007-05-14 |
2013-10-03 |
Astrazeneca Ab |
Methods of reducing eosinophil levels
|
CA3006428A1
(en)
|
2007-06-08 |
2008-12-18 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
PE20131334A1
(es)
|
2007-06-12 |
2013-11-13 |
Ac Immune Sa |
Anticuerpo igg1 humanizado
|
CA2795379A1
(en)
*
|
2007-06-15 |
2008-12-18 |
Centre National De La Recherche Scientifique |
Modifying glycoprotein production in plants
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
PL2586788T3
(pl)
|
2007-07-09 |
2018-05-30 |
Genentech, Inc. |
Zapobieganie redukcji wiązań disiarczkowych podczas rekombinacyjnego wytwarzania polipeptydów
|
WO2009032949A2
(en)
|
2007-09-04 |
2009-03-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
KR101680906B1
(ko)
|
2007-09-26 |
2016-11-30 |
추가이 세이야쿠 가부시키가이샤 |
항체 정상영역 개변체
|
CA2701790A1
(en)
|
2007-10-05 |
2009-04-16 |
Ac Immune S.A. |
Use of humanized anti-beta-amyloid antibody in ocular diseases
|
CN102172395A
(zh)
|
2007-11-07 |
2011-09-07 |
健泰科生物技术公司 |
用于治疗微生物病症的组合物和方法
|
TWI468417B
(zh)
|
2007-11-30 |
2015-01-11 |
Genentech Inc |
抗-vegf抗體
|
JP2011507897A
(ja)
*
|
2007-12-21 |
2011-03-10 |
ジェネンテック, インコーポレイテッド |
リツキシマブ抵抗性関節リウマチ患者の治療
|
CN101965366B
(zh)
*
|
2007-12-26 |
2016-04-27 |
生物测试股份公司 |
靶向cd138的免疫缀合物及其应用
|
US9011864B2
(en)
*
|
2007-12-26 |
2015-04-21 |
Biotest Ag |
Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates
|
CN105418762B
(zh)
|
2007-12-26 |
2019-11-05 |
Xencor公司 |
与FcRn结合改变的Fc变体
|
WO2009080829A1
(en)
*
|
2007-12-26 |
2009-07-02 |
Biotest Ag |
Agents targeting cd138 and uses thereof
|
AU2008339913B2
(en)
*
|
2007-12-26 |
2014-03-20 |
Biotest Ag |
Methods and agents for improving targeting of CD138 expressing tumor cells
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
US20090269339A1
(en)
*
|
2008-04-29 |
2009-10-29 |
Genentech, Inc. |
Responses to immunizations in rheumatoid arthritis patients treated with a cd20 antibody
|
KR101054362B1
(ko)
*
|
2008-07-03 |
2011-08-05 |
재단법인 목암생명공학연구소 |
재조합 단백질의 푸코스 함량을 감소시키는 방법
|
ES2442024T3
(es)
|
2008-07-15 |
2014-02-07 |
Academia Sinica |
Matrices de glucano sobre portaobjetos de vidrio revestidos con aluminio de tipo PTFE y métodos relacionados
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
EP2340305A1
(en)
*
|
2008-09-26 |
2011-07-06 |
Eureka Therapeutics, Inc. |
Cell lines and proteins with variant glycosylation pattern
|
TWI572359B
(zh)
|
2008-10-14 |
2017-03-01 |
建南德克公司 |
免疫球蛋白變異體及其用途
|
MX2011004201A
(es)
|
2008-10-20 |
2011-05-24 |
Abbott Lab |
Desactivacion viral durante purificacion de anticuerpos.
|
TWI610936B
(zh)
*
|
2008-10-20 |
2018-01-11 |
艾伯維有限公司 |
使用蛋白質a親和性層析進行抗體之分離及純化
|
SI2752189T1
(sl)
|
2008-11-22 |
2017-02-28 |
F. Hoffmann-La Roche Ag |
Uporaba anti-vegf protitelesa v kombinaciji s kemoterapijo za zdravljenje prsnega raka
|
AR074777A1
(es)
|
2008-12-19 |
2011-02-09 |
Glaxo Group Ltd |
Proteinas de union a antigeno
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
WO2010075548A2
(en)
|
2008-12-23 |
2010-07-01 |
Genentech, Inc. |
Immunoglobulin variants with altered binding to protein a
|
CA2752510C
(en)
|
2009-02-17 |
2024-01-23 |
Neil Bander |
Methods and kits for diagnosis of cancer and prediction of therapeutic value
|
EP2401696B1
(en)
*
|
2009-02-26 |
2017-06-21 |
Intrexon CEU, Inc. |
Mammalian cell line models and related methods
|
CA2755640C
(en)
|
2009-03-20 |
2018-05-22 |
Genentech, Inc. |
Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr
|
TWI504409B
(zh)
|
2009-03-25 |
2015-10-21 |
Genentech Inc |
新穎抗-α5β1抗體及其用途
|
KR101830024B1
(ko)
|
2009-03-25 |
2018-02-19 |
제넨테크, 인크. |
항-fgfr3 항체 및 그의 사용 방법
|
WO2010115589A1
(en)
|
2009-04-07 |
2010-10-14 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
RU2561041C2
(ru)
*
|
2009-05-06 |
2015-08-20 |
Биотест Аг |
Применения иммуноконъюгатов, мишенью которых является cd138
|
US8815242B2
(en)
|
2009-05-27 |
2014-08-26 |
Synageva Biopharma Corp. |
Avian derived antibodies
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
WO2010146059A2
(en)
|
2009-06-16 |
2010-12-23 |
F. Hoffmann-La Roche Ag |
Biomarkers for igf-1r inhibitor therapy
|
WO2011014457A1
(en)
|
2009-07-27 |
2011-02-03 |
Genentech, Inc. |
Combination treatments
|
KR20120089253A
(ko)
|
2009-07-31 |
2012-08-09 |
제넨테크, 인크. |
Bv8? 또는 g?csf?길항제를 이용한 종양 전이의 억제
|
PT2464725T
(pt)
|
2009-08-11 |
2020-05-21 |
Hoffmann La Roche |
Produção de proteínas em meios de cultura celular isentos de glutamina
|
TWI451875B
(zh)
|
2009-08-15 |
2014-09-11 |
建南德克公司 |
用於治療先前治療過之乳癌之抗-血管新生療法
|
TWI412375B
(zh)
|
2009-08-28 |
2013-10-21 |
Roche Glycart Ag |
人類化抗cdcp1抗體
|
KR101528013B1
(ko)
*
|
2009-08-31 |
2015-06-16 |
로슈 글리카트 아게 |
친화성-성숙된 인간화된 항-cea 단일클론 항체
|
US9321823B2
(en)
|
2009-09-02 |
2016-04-26 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
ES2534646T3
(es)
|
2009-10-22 |
2015-04-27 |
F. Hoffmann-La Roche Ag |
Anticuerpos anti-hepsina y métodos de uso de los mismos
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
EP2496600A1
(en)
|
2009-11-04 |
2012-09-12 |
Fabrus LLC |
Methods for affinity maturation-based antibody optimization
|
WO2011057120A1
(en)
|
2009-11-05 |
2011-05-12 |
Genentech, Inc. |
Methods and composition for secretion of heterologous polypeptides
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
CN102753194B
(zh)
|
2009-12-02 |
2015-07-08 |
伊麦吉纳博公司 |
靶向人前列腺特异性膜抗原的j591微抗体和双抗体
|
TWI505836B
(zh)
|
2009-12-11 |
2015-11-01 |
Genentech Inc |
抗-vegf-c抗體及其使用方法
|
SG181905A1
(en)
|
2009-12-23 |
2012-07-30 |
Genentech Inc |
Anti-bv8 antibodies and uses thereof
|
US8362210B2
(en)
|
2010-01-19 |
2013-01-29 |
Xencor, Inc. |
Antibody variants with enhanced complement activity
|
PE20121702A1
(es)
|
2010-01-28 |
2012-12-14 |
Glaxo Group Ltd |
Proteinas de enlace cd127
|
EA201290630A1
(ru)
|
2010-02-09 |
2013-03-29 |
Глаксо Груп Лимитед |
Лечение расстройства обмена веществ
|
MX341687B
(es)
|
2010-02-10 |
2016-08-30 |
Immunogen Inc |
"anticuerpos cd20 y su utilización".
|
CA2784211C
(en)
|
2010-02-18 |
2019-12-24 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
WO2011101328A2
(en)
|
2010-02-18 |
2011-08-25 |
Roche Glycart Ag |
Treatment with a humanized igg class anti egfr antibody and an antibody against insulin like growth factor 1 receptor
|
MX2012009554A
(es)
|
2010-02-23 |
2012-11-23 |
Hoffmann La Roche |
Terapia anti-angiogenesis para el tratamiento del cancer ovarico.
|
UA108227C2
(xx)
|
2010-03-03 |
2015-04-10 |
|
Антигензв'язуючий білок
|
TW201138823A
(en)
|
2010-03-24 |
2011-11-16 |
Genentech Inc |
Anti-LRP6 antibodies
|
EP2374816B1
(en)
|
2010-04-07 |
2016-09-28 |
Agency For Science, Technology And Research |
Binding molecules against Chikungunya virus and uses thereof
|
WO2011124635A1
(en)
|
2010-04-07 |
2011-10-13 |
Humalys |
Binding molecules against chikungunya virus and uses thereof
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
CA2835489C
(en)
|
2010-05-10 |
2018-03-06 |
Chi-Huey Wong |
Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
WO2011153243A2
(en)
|
2010-06-02 |
2011-12-08 |
Genentech, Inc. |
Anti-angiogenesis therapy for treating gastric cancer
|
UY33421A
(es)
|
2010-06-03 |
2011-12-30 |
Glaxo Wellcome House |
Proteinas de union al antígeno humanizados
|
WO2011153346A1
(en)
|
2010-06-03 |
2011-12-08 |
Genentech, Inc. |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
CA2794731C
(en)
|
2010-06-18 |
2019-03-19 |
Genentech, Inc. |
Anti-axl antibodies and methods of use
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
CN103097418A
(zh)
|
2010-07-09 |
2013-05-08 |
霍夫曼-拉罗奇有限公司 |
抗神经毡蛋白抗体及使用方法
|
EP2409989A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Method to improve glycosylation profile for antibody
|
EP2409712A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
|
EP2409993A1
(en)
|
2010-07-19 |
2012-01-25 |
International-Drug-Development-Biotech |
Anti-CD19 antibody having ADCC function with improved glycosylation profile
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
EP3696195B1
(en)
|
2010-07-23 |
2024-02-14 |
Trustees of Boston University |
Anti-despr inhibitors as therapeutics for inhibition of pathological angiogenesis and tumor cell invasiveness and for molecular imaging and targeted delivery
|
BR112013002535A2
(pt)
|
2010-08-03 |
2019-09-24 |
Hoffmann La Roche |
biomarcadores de leucemia linfocítica crônica (cll)
|
EP2600898A1
(en)
|
2010-08-05 |
2013-06-12 |
F.Hoffmann-La Roche Ag |
Anti-mhc antibody anti-viral cytokine fusion protein
|
MX358859B
(es)
|
2010-08-13 |
2018-09-05 |
Roche Glycart Ag |
Anticuerpos anti-fap y métodos de utilización.
|
JP5841149B2
(ja)
|
2010-08-13 |
2016-01-13 |
ロシュ グリクアート アーゲー |
抗テネイシンca2抗体及び使用の方法
|
KR101603001B1
(ko)
|
2010-08-25 |
2016-03-11 |
에프. 호프만-라 로슈 아게 |
Il-18r1에 대한 항체 및 그의 용도
|
JP2013537966A
(ja)
|
2010-08-31 |
2013-10-07 |
ジェネンテック, インコーポレイテッド |
バイオマーカー及び治療の方法
|
CA2813738A1
(en)
|
2010-10-05 |
2012-04-12 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
KR20200059320A
(ko)
|
2010-11-08 |
2020-05-28 |
제넨테크, 인크. |
피하 투여용 항―il―6 수용체 항체
|
JP6163429B2
(ja)
|
2010-11-10 |
2017-07-12 |
ジェネンテック, インコーポレイテッド |
神経疾患免疫治療のための方法及び組成物
|
BR112013012627A2
(pt)
|
2010-11-23 |
2016-10-04 |
Glaxo Group Ltd |
proteína de ligação de antígeno, polinucleotídeo, composição farmacêutica, e uso da referida composição
|
MX2013005847A
(es)
|
2010-11-24 |
2013-12-12 |
Glaxo Group Ltd |
Proteinas de union a antigeno multiespecificas que eligen como blanco a hgf.
|
EP3208282A1
(en)
|
2010-11-30 |
2017-08-23 |
F. Hoffmann-La Roche AG |
Low affinity anti transferrin receptor and their use to transfer therapeutic scfv across the blood brain barrier
|
KR101923282B1
(ko)
|
2010-12-16 |
2018-11-28 |
제넨테크, 인크. |
Th2 억제에 관한 진단 및 치료
|
NZ610976A
(en)
|
2010-12-20 |
2015-07-31 |
Genentech Inc |
Anti-mesothelin antibodies and immunoconjugates
|
WO2012088313A1
(en)
|
2010-12-22 |
2012-06-28 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
EP2482074A1
(en)
*
|
2011-01-27 |
2012-08-01 |
Medizinische Hochschule Hannover |
Methods and means for diagnosing vasculitis
|
CN103476433A
(zh)
|
2011-02-10 |
2013-12-25 |
罗切格利卡特公司 |
改良的免疫疗法
|
LT3489255T
(lt)
|
2011-02-10 |
2021-08-25 |
Roche Glycart Ag |
Mutantiniai interleukino-2 polipeptidai
|
RU2013141078A
(ru)
|
2011-02-28 |
2015-04-10 |
Ф. Хоффманн-Ля Рош Аг |
Одновалентные антигенсвязывающие белки
|
ES2549638T3
(es)
|
2011-02-28 |
2015-10-30 |
F. Hoffmann-La Roche Ag |
Proteínas de unión a antígeno
|
RS56793B1
(sr)
|
2011-03-02 |
2018-04-30 |
Roche Glycart Ag |
Cea antitela
|
CA2828890A1
(en)
|
2011-04-07 |
2012-10-11 |
Genentech, Inc. |
Anti-fgfr4 antibodies and methods of use
|
EP2702077A2
(en)
|
2011-04-27 |
2014-03-05 |
AbbVie Inc. |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
WO2012146630A1
(en)
|
2011-04-29 |
2012-11-01 |
F. Hoffmann-La Roche Ag |
N-terminal acylated polypeptides, methods for their production and uses thereof
|
ES2567276T3
(es)
|
2011-05-12 |
2016-04-21 |
Genentech, Inc. |
Método de LC-MS/MS de monitoreo de múltiples reacciones para detectar anticuerpos terapéuticos en muestras de animales usando péptidos de cambio de marco
|
SG194917A1
(en)
|
2011-05-16 |
2013-12-30 |
Genentech Inc |
Fgfr1 agonists and methods of use
|
CN106279418A
(zh)
|
2011-05-27 |
2017-01-04 |
葛兰素集团有限公司 |
Bcma(cd269/tnfrsf17)结合蛋白
|
CN103596984B
(zh)
|
2011-06-15 |
2016-04-13 |
霍夫曼-拉罗奇有限公司 |
抗-人epo受体的抗体及使用方法
|
ES2667864T3
(es)
|
2011-06-22 |
2018-05-14 |
F. Hoffmann-La Roche Ag |
Eliminación de células diana mediante linfocitos T citotóxicos específicos de virus en circulación usando complejos que comprenden MHC de clase I
|
CN107090038A
(zh)
|
2011-06-30 |
2017-08-25 |
霍夫曼-拉罗奇有限公司 |
抗c‑met抗体配制剂
|
US20130022551A1
(en)
|
2011-07-22 |
2013-01-24 |
Trustees Of Boston University |
DEspR ANTAGONISTS AND AGONISTS AS THERAPEUTICS
|
EP2736925A2
(en)
|
2011-07-27 |
2014-06-04 |
Glaxo Group Limited |
Anti-vegf single variable domains fused to fc domains
|
BR112014003431A2
(pt)
|
2011-08-17 |
2017-06-13 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, agente farmacêutico, uso do anticorpo, método de tratamento de um indivíduo que tem câncer e método de aumento de tempo para recorrência de tumor
|
WO2013025944A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
ES2686327T3
(es)
|
2011-08-23 |
2018-10-17 |
Roche Glycart Ag |
Moléculas de unión a antígeno biespecíficas
|
CA2844141A1
(en)
|
2011-08-23 |
2013-02-28 |
Roche Glycart Ag |
Anti-mcsp antibodies
|
CN103930781A
(zh)
|
2011-09-15 |
2014-07-16 |
霍夫曼-拉罗奇有限公司 |
促进分化的方法
|
EP2758055A1
(en)
|
2011-09-19 |
2014-07-30 |
F.Hoffmann-La Roche Ag |
Combination treatments comprising c-met antagonists and b-raf antagonists
|
AU2012319150B2
(en)
|
2011-10-05 |
2017-08-17 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
JP6532678B2
(ja)
|
2011-10-14 |
2019-06-19 |
ジェネンテック, インコーポレイテッド |
抗HtrA1抗体及び使用方法
|
JP6356605B2
(ja)
|
2011-10-19 |
2018-07-11 |
ロシュ グリクアート アーゲー |
フコシル化抗体の分離法
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
EP2776051A4
(en)
|
2011-10-28 |
2015-06-17 |
Hoffmann La Roche |
THERAPEUTIC COMBINATIONS AND METHOD FOR THE TREATMENT OF MELANOMA
|
AU2012340826A1
(en)
|
2011-11-21 |
2014-05-29 |
Genentech, Inc. |
Purification of anti-c-met antibodies
|
US20140335084A1
(en)
|
2011-12-06 |
2014-11-13 |
Hoffmann-La Roche Inc. |
Antibody formulation
|
US10117932B2
(en)
|
2011-12-08 |
2018-11-06 |
Biotest Ag |
Uses of immunoconjugates targeting CD138
|
WO2013092720A1
(en)
|
2011-12-22 |
2013-06-27 |
F. Hoffmann-La Roche Ag |
Full length antibody display system for eukaryotic cells and its use
|
BR112014014239B1
(pt)
|
2011-12-22 |
2021-10-13 |
F. Hoffmann-La Roche Ag |
Método para selecionar uma célula recombinante de mamífero transfectada estável, método para produzir um anticorpo e vetor de expressão
|
EP3816284A1
(en)
|
2011-12-22 |
2021-05-05 |
F. Hoffmann-La Roche AG |
Expression vector for antibody production in eukaryotic cells
|
AR089434A1
(es)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
Procedimiento para preparar formulaciones con alta concentracion de proteinas
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
CN104520321A
(zh)
|
2012-01-09 |
2015-04-15 |
斯克利普斯研究所 |
超长互补决定区及其用途
|
EP2802601B1
(en)
|
2012-01-09 |
2019-11-13 |
The Scripps Research Institute |
Humanized antibodies with ultralong cdr3s
|
CA2862424A1
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
JP6242813B2
(ja)
|
2012-01-18 |
2017-12-06 |
ジェネンテック, インコーポレイテッド |
抗lrp5抗体及び使用方法
|
WO2013113641A1
(en)
|
2012-01-31 |
2013-08-08 |
Roche Glycart Ag |
Use of nkp46 as a predictive biomarker for cancer treatment with adcc- enhanced antibodies
|
AU2013216753B2
(en)
|
2012-02-11 |
2017-09-21 |
Genentech, Inc. |
R-spondin translocations and methods using the same
|
KR102069397B1
(ko)
|
2012-02-15 |
2020-01-22 |
에프. 호프만-라 로슈 아게 |
Fc-수용체 기재 친화성 크로마토그래피
|
WO2013127465A1
(en)
|
2012-03-02 |
2013-09-06 |
Roche Glycart Ag |
Predicitive biomarker for cancer treatment with adcc enhanced antibodies
|
RU2014136886A
(ru)
|
2012-03-27 |
2016-05-20 |
Дженентек, Инк. |
Диагностика и виды лечения, связанные с ингибиторами her3
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
US9181572B2
(en)
|
2012-04-20 |
2015-11-10 |
Abbvie, Inc. |
Methods to modulate lysine variant distribution
|
AU2013256596A1
(en)
|
2012-05-01 |
2014-10-09 |
Genentech, Inc. |
Anti-PMEL17 antibodies and immunoconjugates
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
ES2682761T3
(es)
|
2012-05-18 |
2018-09-21 |
Genentech, Inc. |
Formulaciones de anticuerpos monoclonales de alta concentración
|
BR112014028838A2
(pt)
|
2012-05-21 |
2020-05-12 |
Genentech Inc |
Usos de um anticorpo, método para fazer um anticorpo e anticorpos
|
US9695454B2
(en)
|
2012-05-23 |
2017-07-04 |
Glykos Finland Oy |
Production of fucosylated glycoproteins
|
RU2625771C2
(ru)
|
2012-05-23 |
2017-07-18 |
Дженентек, Инк. |
Способ отбора терапевтических средств
|
WO2013176754A1
(en)
|
2012-05-24 |
2013-11-28 |
Abbvie Inc. |
Novel purification of antibodies using hydrophobic interaction chromatography
|
CN103463633B
(zh)
*
|
2012-06-07 |
2016-03-30 |
复旦大学 |
一种靶向的嵌合乙肝核心抗原治疗性疫苗及其用途
|
RU2015101113A
(ru)
|
2012-06-15 |
2016-08-10 |
Дженентек, Инк. |
Антитела против pcsk9, составы, дозы и способы применения
|
US20140004121A1
(en)
|
2012-06-27 |
2014-01-02 |
Amgen Inc. |
Anti-mesothelin binding proteins
|
CN104394886B
(zh)
|
2012-07-04 |
2017-05-24 |
弗·哈夫曼-拉罗切有限公司 |
抗茶碱抗体及使用方法
|
JP6148729B2
(ja)
|
2012-07-04 |
2017-06-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
共有結合している抗原−抗体結合体
|
KR20150030755A
(ko)
|
2012-07-04 |
2015-03-20 |
에프. 호프만-라 로슈 아게 |
항-바이오틴 항체 및 사용 방법
|
KR20150030693A
(ko)
|
2012-07-05 |
2015-03-20 |
제넨테크, 인크. |
발현 및 분비 시스템
|
BR112015000437A2
(pt)
|
2012-07-09 |
2017-06-27 |
Genentech Inc |
imunoconjugados, formulação farmacêutica, métodos de tratamento e de inbir a proliferação de uma célula
|
WO2014011521A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti - cd79b antibodies
|
TW201406785A
(zh)
|
2012-07-09 |
2014-02-16 |
Genentech Inc |
抗cd22抗體及免疫結合物
|
SG11201500142RA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti-cd22 antibodies
|
KR101774121B1
(ko)
|
2012-07-13 |
2017-09-01 |
로슈 글리카트 아게 |
이중특이적 항-vegf/항-ang-2 항체 및 안 혈관 질환의 치료에 있어서 이의 용도
|
EP3381943B1
(en)
|
2012-07-25 |
2022-03-16 |
Celldex Therapeutics, Inc. |
Anti-kit antibodies and uses thereof
|
AU2013301582B2
(en)
|
2012-08-07 |
2018-09-06 |
Roche Glycart Ag |
Composition comprising two antibodies engineered to have reduced and increased effector function
|
WO2014031498A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
EP2888238A4
(en)
|
2012-08-21 |
2016-01-27 |
Academia Sinica |
BENZOCYCLO-OCTYNE COMPOUNDS AND USES THEREOF
|
WO2014029752A1
(en)
|
2012-08-22 |
2014-02-27 |
Glaxo Group Limited |
Anti lrp6 antibodies
|
CA2879496C
(en)
|
2012-08-29 |
2024-01-09 |
F. Hoffmann-La Roche Ag |
Blood brain barrier shuttle
|
SG11201504249XA
(en)
|
2012-09-02 |
2015-07-30 |
Abbvie Inc |
Methods to control protein heterogeneity
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
KR102158467B1
(ko)
|
2012-09-07 |
2020-09-25 |
제넨테크, 인크. |
Ii형 항-cd20 항체와 선택적 bcl-2 억제제와의 병용 치료요법
|
ES2530968T3
(es)
|
2012-10-12 |
2015-03-09 |
Spirogen Sarl |
Pirrolobenzodiazepinas y conjugados de las mismas
|
EP2912060B1
(en)
|
2012-10-29 |
2019-12-25 |
The University of North Carolina at Chapel Hill |
Compositions and methods for inhibiting pathogen infection
|
EP2914621B1
(en)
|
2012-11-05 |
2023-06-07 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
MA38165A1
(fr)
|
2012-11-08 |
2018-07-31 |
Hoffmann La Roche |
Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
|
PE20150945A1
(es)
|
2012-11-13 |
2015-06-26 |
Genentech Inc |
Anticuerpos de antihemaglutinina y metodos de uso
|
AU2013360775B2
(en)
|
2012-12-21 |
2018-04-12 |
F. Hoffmann-La Roche Ag |
Disulfide-linked multivalent MHC class I comprising multi-function proteins
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014114595A1
(en)
|
2013-01-23 |
2014-07-31 |
Roche Glycart Ag |
Predictive biomarker for cancer treatment with adcc-enhanced antibodies
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
AR094780A1
(es)
|
2013-02-13 |
2015-08-26 |
Laboratoire Français Du Fractionnement Et Des Biotechnologies |
ANTICUERPOS ANTI-TNF-a ALTAMENTE GALACTOSILADOS Y SUS USOS
|
WO2014140927A2
(en)
|
2013-02-13 |
2014-09-18 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Proteins with modified glycosylation and methods of production thereof
|
BR112015018418A2
(pt)
|
2013-02-22 |
2017-07-18 |
Hoffmann La Roche |
métodos para tratar câncer, para aumentar a eficácia de um tratamento, para adiar e/ou prevenir o desenvolvimento de câncer, para aumentar a sensibilidade a um terapêutico direcionado, para estender o período de sensibilidade, para estender a duração de resposta a um terapêutico direcionado e produto farmacêutico
|
KR20150123811A
(ko)
|
2013-02-26 |
2015-11-04 |
로슈 글리카트 아게 |
항-mcsp 항체
|
MX2015011428A
(es)
|
2013-03-06 |
2016-02-03 |
Genentech Inc |
Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
|
EP2830651A4
(en)
|
2013-03-12 |
2015-09-02 |
Abbvie Inc |
HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
|
ES2687439T3
(es)
|
2013-03-13 |
2018-10-25 |
Medimmune Limited |
Pirrolobenzodiazepinas y conjugados de las mismas
|
EP3299391B1
(en)
|
2013-03-14 |
2019-12-04 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
EP2968565A2
(en)
|
2013-03-14 |
2016-01-20 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
US8921526B2
(en)
|
2013-03-14 |
2014-12-30 |
Abbvie, Inc. |
Mutated anti-TNFα antibodies and methods of their use
|
SG11201507477XA
(en)
|
2013-03-14 |
2015-10-29 |
Genentech Inc |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
US9499614B2
(en)
|
2013-03-14 |
2016-11-22 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
EP3712177A1
(en)
|
2013-03-15 |
2020-09-23 |
GlaxoSmithKline Intellectual Property Development Limited |
Anti-lag-3 binding proteins
|
MX2015011444A
(es)
|
2013-03-15 |
2015-12-16 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento del cancer hepatico.
|
CA2905798C
(en)
|
2013-03-15 |
2023-01-24 |
Genentech, Inc. |
Biomarkers and methods of treating pd-1 and pd-l1 related conditions
|
EP2968537A1
(en)
|
2013-03-15 |
2016-01-20 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
KR102233349B1
(ko)
|
2013-03-15 |
2021-03-31 |
에이씨 이뮨 에스.에이. |
항-타우(tau) 항체 및 사용 방법
|
US20140328849A1
(en)
|
2013-03-15 |
2014-11-06 |
Genentech, Inc. |
Anti-crth2 antibodies and methods of use
|
TR201809571T4
(tr)
|
2013-03-15 |
2018-07-23 |
Hoffmann La Roche |
Ll-22 polipeptidleri ile ıl-22 fc füzyon proteinleri ve kullanım yöntemleri.
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
PE20151807A1
(es)
|
2013-04-29 |
2015-12-02 |
Hoffmann La Roche |
Anticuerpos modificados de union a fcrn humano y metodo de utilizacion
|
EP3327034A1
(en)
|
2013-04-29 |
2018-05-30 |
F. Hoffmann-La Roche AG |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
RU2687043C2
(ru)
|
2013-04-29 |
2019-05-06 |
Ф. Хоффманн-Ля Рош Аг |
МОДИФИЦИРОВАННЫЕ АСИММЕТРИЧНЫЕ АНТИТЕЛА, СВЯЗЫВАЮЩИЕ Fc-РЕЦЕПТОР, И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
MX2015015970A
(es)
|
2013-05-20 |
2016-09-08 |
Genentech Inc |
Anticuerpos receptores de antitransferina y metodos de uso.
|
EP3013365B1
(en)
|
2013-06-26 |
2019-06-05 |
Academia Sinica |
Rm2 antigens and use thereof
|
WO2014210564A1
(en)
|
2013-06-27 |
2014-12-31 |
Academia Sinica |
Glycan conjugates and use thereof
|
JP6687520B2
(ja)
|
2013-07-18 |
2020-04-22 |
トーラス バイオサイエンシズ リミテッド ライアビリティ カンパニー |
極めて長い相補性決定領域を有するヒト化抗体
|
WO2015017146A2
(en)
|
2013-07-18 |
2015-02-05 |
Fabrus, Inc. |
Antibodies with ultralong complementarity determining regions
|
TWI679021B
(zh)
|
2013-08-01 |
2019-12-11 |
美商戊瑞治療有限公司 |
無海藻糖基化抗fgfr2iiib抗體
|
KR20160042438A
(ko)
|
2013-08-12 |
2016-04-19 |
제넨테크, 인크. |
보체-연관 상태의 치료를 위한 조성물 및 방법
|
JP6486368B2
(ja)
|
2013-09-06 |
2019-03-20 |
アカデミア シニカAcademia Sinica |
改変されたグリコシル基を含む糖脂質を用いたヒトiNKT細胞の活性化
|
RU2016109247A
(ru)
|
2013-09-17 |
2017-10-19 |
Дженентек, Инк. |
Способы применения антител к lgr5
|
EP3052640A2
(en)
|
2013-10-04 |
2016-08-10 |
AbbVie Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
KR20160068855A
(ko)
|
2013-10-11 |
2016-06-15 |
제넨테크, 인크. |
Nsp4 억제제 및 사용 방법
|
CN105813654B
(zh)
|
2013-10-11 |
2019-05-31 |
美国政府(由卫生和人类服务部的部长所代表) |
Tem8抗体及其用途
|
CN105612182B
(zh)
|
2013-10-11 |
2019-12-10 |
豪夫迈·罗氏有限公司 |
多特异性结构域交换共有可变轻链抗体
|
US8946395B1
(en)
|
2013-10-18 |
2015-02-03 |
Abbvie Inc. |
Purification of proteins using hydrophobic interaction chromatography
|
CN105744954B
(zh)
|
2013-10-18 |
2021-03-05 |
豪夫迈·罗氏有限公司 |
抗rspo2和/或抗rspo3抗体及其用途
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
MX2016005159A
(es)
|
2013-10-23 |
2016-07-05 |
Genentech Inc |
Metodos de diagnostico y tratamiento de trastornos eosinofilicos.
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
CA2924268C
(en)
|
2013-11-21 |
2021-05-18 |
F. Hoffmann-La Roche Ag |
Anti-alpha-synuclein antibodies and methods of use
|
CA2930886C
(en)
|
2013-12-09 |
2024-05-21 |
Christopher R. Bebbington |
Anti-siglec-8 antibodies and methods of use thereof
|
KR20160098328A
(ko)
|
2013-12-13 |
2016-08-18 |
제넨테크, 인크. |
항-cd33 항체 및 면역접합체
|
US20160333063A1
(en)
|
2013-12-13 |
2016-11-17 |
The General Hospital Corporation |
Soluble high molecular weight (hmw) tau species and applications thereof
|
SG11201604979WA
(en)
|
2013-12-17 |
2016-07-28 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
ES2763429T5
(es)
|
2013-12-17 |
2023-06-21 |
Hoffmann La Roche |
Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
|
PE20210648A1
(es)
|
2013-12-17 |
2021-03-26 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
CN105899535A
(zh)
|
2013-12-17 |
2016-08-24 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
KR102452173B1
(ko)
|
2013-12-24 |
2022-10-17 |
더 보드 오브 리전츠 오브 더 유니버시티 오브 텍사스 시스템 |
Fcrn 길항제 및 사용방법
|
CA2933384A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
BR112016014945A2
(pt)
|
2014-01-03 |
2018-01-23 |
F. Hoffmann-La Roche Ag |
conjugado, formulação farmacêutica e uso
|
KR102278979B1
(ko)
|
2014-01-03 |
2021-07-19 |
에프. 호프만-라 로슈 아게 |
공유적으로 연결된 헬리카-항-헬리카 항체 접합체 및 그의 용도
|
CN111057151B
(zh)
|
2014-01-06 |
2022-05-03 |
豪夫迈·罗氏有限公司 |
单价血脑屏障穿梭模块
|
RU2727639C2
(ru)
|
2014-01-15 |
2020-07-22 |
Ф.Хоффманн-Ля Рош Аг |
Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
AU2015206370A1
(en)
|
2014-01-16 |
2016-07-07 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CA2935393A1
(en)
|
2014-01-24 |
2015-07-30 |
Genentech, Inc. |
Methods of using anti-steap1 antibodies and immunoconjugates
|
DK3102197T3
(en)
|
2014-02-04 |
2018-11-19 |
Genentech Inc |
Smoothened mutant and methods for its use
|
AU2015213741B2
(en)
|
2014-02-08 |
2020-10-08 |
Genentech, Inc. |
Methods of treating Alzheimer's Disease
|
KR20160111039A
(ko)
|
2014-02-08 |
2016-09-23 |
제넨테크, 인크. |
알츠하이머 질환을 치료하는 방법
|
US9518121B2
(en)
|
2014-02-12 |
2016-12-13 |
Genentech, Inc. |
Anti-Jagged1 antibodies and methods of use
|
EA201691473A1
(ru)
|
2014-02-21 |
2016-12-30 |
Дженентек, Инк. |
Биспецифические анти-il-13/il-17 антитела и их применение
|
EP4014995A1
(en)
|
2014-02-28 |
2022-06-22 |
Allakos Inc. |
Methods and compositions for treating siglec-8 associated diseases
|
SI3116999T1
(sl)
|
2014-03-14 |
2021-12-31 |
F. Hoffmann - La Roche Ag |
Postopki in sestavki za izločanje heterolognih polipeptidov
|
US20170107294A1
(en)
|
2014-03-21 |
2017-04-20 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
MX2016012285A
(es)
|
2014-03-24 |
2017-01-23 |
Genentech Inc |
Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
|
TWI797430B
(zh)
|
2014-03-27 |
2023-04-01 |
中央研究院 |
反應性標記化合物及其用途
|
SG11201607969XA
(en)
|
2014-03-31 |
2016-10-28 |
Genentech Inc |
Anti-ox40 antibodies and methods of use
|
WO2015153514A1
(en)
|
2014-03-31 |
2015-10-08 |
Genentech, Inc. |
Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
JP2017522861A
(ja)
|
2014-05-22 |
2017-08-17 |
ジェネンテック, インコーポレイテッド |
抗gpc3抗体及びイムノコンジュゲート
|
JP2017524371A
(ja)
|
2014-05-23 |
2017-08-31 |
ジェネンテック, インコーポレイテッド |
Mitバイオマーカーとその使用方法
|
JP2017518989A
(ja)
|
2014-05-27 |
2017-07-13 |
アカデミア シニカAcademia Sinica |
抗cd20糖操作抗体群およびその使用
|
TWI679020B
(zh)
|
2014-05-27 |
2019-12-11 |
中央研究院 |
抗her2醣抗體及其用途
|
CN107074945B
(zh)
|
2014-05-27 |
2021-08-24 |
中央研究院 |
增进抗体功效的通用糖型的组合物及方法
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
TWI732738B
(zh)
|
2014-05-28 |
2021-07-11 |
中央研究院 |
抗TNF-α醣抗體及其用途
|
EP3155015A1
(en)
|
2014-06-11 |
2017-04-19 |
F. Hoffmann-La Roche AG |
Anti-lgr5 antibodies and uses thereof
|
JP2017517552A
(ja)
|
2014-06-13 |
2017-06-29 |
ジェネンテック, インコーポレイテッド |
抗癌剤耐性の治療及び防止方法
|
CN106687476B
(zh)
|
2014-06-26 |
2020-11-13 |
豪夫迈·罗氏有限公司 |
抗brdu抗体及使用方法
|
EP3309174B1
(en)
|
2014-07-11 |
2022-05-11 |
Ventana Medical Systems, Inc. |
Anti-pd-l1 antibodies and diagnostic uses thereof
|
US9914774B2
(en)
|
2014-07-11 |
2018-03-13 |
Genentech, Inc. |
Notch pathway inhibition
|
AU2015293949B2
(en)
|
2014-07-21 |
2019-07-25 |
Teknologian Tutkimuskeskus Vtt Oy |
Production of glycoproteins with mammalian-like N-glycans in filamentous fungi
|
CR20170060A
(es)
|
2014-08-19 |
2017-04-18 |
Merck Sharp & Dohme |
Anticuerpos anti tigit
|
ES2913865T3
(es)
|
2014-08-28 |
2022-06-06 |
Bioatla Inc |
Receptores de antígeno quimérico condicionalmente activos para células T modificadas
|
TWI805109B
(zh)
|
2014-08-28 |
2023-06-11 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
US9879042B2
(en)
|
2014-09-08 |
2018-01-30 |
Academia Sinica |
Human iNKT cell activation using glycolipids
|
WO2016037644A1
(en)
|
2014-09-10 |
2016-03-17 |
Medimmune Limited |
Pyrrolobenzodiazepines and conjugates thereof
|
AR101848A1
(es)
|
2014-09-12 |
2017-01-18 |
Genentech Inc |
Anticuerpos de anti-b7-h4 e inmunoconjugados
|
MA40579A
(fr)
|
2014-09-12 |
2016-03-17 |
Genentech Inc |
Anticorps anti-cll-1 et immunoconjugués
|
SI3191135T1
(sl)
|
2014-09-12 |
2021-01-29 |
Genentech, Inc. |
Anti-HER2 protitelesa in imunokonjugati
|
MX2017003472A
(es)
|
2014-09-17 |
2017-10-31 |
Genentech Inc |
Inmunoconjugados que comprenden anticuerpos anti-her2.
|
PT3262071T
(pt)
|
2014-09-23 |
2020-06-16 |
H Hoffnabb La Roche Ag |
Métodos de utilização de imunoconjugados anti-cd79b
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
JP2017536102A
(ja)
|
2014-10-16 |
2017-12-07 |
ジェネンテック, インコーポレイテッド |
抗アルファ−シヌクレイン抗体及び使用方法
|
WO2016059602A2
(en)
|
2014-10-16 |
2016-04-21 |
Glaxo Group Limited |
Methods of treating cancer and related compositions
|
WO2016070001A1
(en)
|
2014-10-31 |
2016-05-06 |
Jounce Therapeutics, Inc. |
Methods of treating conditions with antibodies that bind b7-h4
|
SG11201703521UA
(en)
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Methods and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
SG11201703448QA
(en)
|
2014-11-03 |
2017-05-30 |
Genentech Inc |
Assays for detecting t cell immune subsets and methods of use thereof
|
CN107108740B
(zh)
|
2014-11-05 |
2021-09-17 |
豪夫迈·罗氏有限公司 |
抗fgfr2/3抗体及其使用方法
|
KR20170072343A
(ko)
|
2014-11-06 |
2017-06-26 |
제넨테크, 인크. |
Ox40 결합 효능제 및 tigit 억제제를 포함하는 병용 요법
|
CA2960797A1
(en)
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn-binding and methods of use
|
MX2017005150A
(es)
|
2014-11-06 |
2017-08-08 |
Hoffmann La Roche |
Variantes de region fc con propiedades modificadas de union a receptor neonatal fc (fcrn) y proteina a.
|
CN107105632A
(zh)
|
2014-11-10 |
2017-08-29 |
豪夫迈·罗氏有限公司 |
肾病动物模型及其治疗剂
|
CR20170240A
(es)
|
2014-11-10 |
2018-04-03 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y sus usos
|
EP3875481A1
(en)
|
2014-11-14 |
2021-09-08 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
JP6873901B2
(ja)
|
2014-11-14 |
2021-05-19 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
Tnfファミリーリガンド三量体を含む抗原結合分子
|
SG11201703605QA
(en)
|
2014-11-17 |
2017-06-29 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
JP6779876B2
(ja)
|
2014-11-19 |
2020-11-04 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
US11008403B2
(en)
|
2014-11-19 |
2021-05-18 |
Genentech, Inc. |
Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
|
JP6859259B2
(ja)
|
2014-11-19 |
2021-04-14 |
ジェネンテック, インコーポレイテッド |
BACElに対する抗体及び神経疾患免疫療法のためのその使用
|
US10160799B2
(en)
|
2014-11-19 |
2018-12-25 |
Axon Neuroscience Se |
Humanized tau antibodies in a alzheimer's disease
|
ES2835823T3
(es)
|
2014-11-20 |
2021-06-23 |
Hoffmann La Roche |
Politerapia de moléculas de unión a antígeno biespecíficas activadoras de linfocitos T para CD3 y para el receptor de folato 1 (FolR1) y antagonistas de la unión al eje de PD-1
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
多重特異性抗体
|
CR20170230A
(es)
|
2014-12-05 |
2017-11-07 |
Genentech Inc |
Anticuerpos anti-cd79b y métodos de uso
|
WO2016094566A2
(en)
|
2014-12-10 |
2016-06-16 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
MY183415A
(en)
|
2014-12-19 |
2021-02-18 |
Chugai Pharmaceutical Co Ltd |
Anti-c5 antibodies and methods of use
|
WO2016111947A2
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CN107428833B
(zh)
|
2015-01-16 |
2021-11-02 |
朱诺治疗学股份有限公司 |
Ror1特异性抗体和嵌合抗原受体
|
US20180016327A1
(en)
|
2015-01-22 |
2018-01-18 |
Chugai Seiyaku Kabushiki Kaisha |
A Combination of Two or More Anti-C5 Antibodies and Methods of Use
|
EP3789766A1
(en)
|
2015-01-24 |
2021-03-10 |
Academia Sinica |
Novel glycan conjugates and methods of use thereof
|
CN107407677B
(zh)
|
2015-01-28 |
2020-07-17 |
豪夫迈·罗氏有限公司 |
多发性硬化的基因表达标志和治疗
|
WO2016126972A1
(en)
|
2015-02-04 |
2016-08-11 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP3253778A1
(en)
|
2015-02-05 |
2017-12-13 |
Chugai Seiyaku Kabushiki Kaisha |
Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
|
US10301377B2
(en)
|
2015-02-24 |
2019-05-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
|
EP3268391B1
(en)
|
2015-03-09 |
2021-08-11 |
argenx BVBA |
Methods of reducing serum levels of fc-containing agents using fcrn antagonsits
|
JP2018511797A
(ja)
|
2015-03-16 |
2018-04-26 |
ジェネンテック, インコーポレイテッド |
IL−13の検出方法及び定量方法並びにTh2関連疾患の診断及び治療における使用
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
DK3271389T3
(da)
|
2015-03-20 |
2020-04-27 |
Us Health |
Neutraliserende antistoffer mod gp120 og anvendelse deraf
|
KR20230164243A
(ko)
|
2015-03-23 |
2023-12-01 |
조운스 테라퓨틱스, 인크. |
Icos에 대한 항체
|
US10584167B2
(en)
|
2015-03-23 |
2020-03-10 |
Bayer Pharma Aktiengesellschaft |
Anti-CEACAM6 antibodies and uses thereof
|
CA2979732A1
(en)
|
2015-04-03 |
2016-10-06 |
Eureka Therapeutics, Inc. |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
CN115932273A
(zh)
|
2015-04-24 |
2023-04-07 |
豪夫迈·罗氏有限公司 |
鉴定包含结合多肽的细菌的方法
|
CN107709363A
(zh)
|
2015-05-01 |
2018-02-16 |
基因泰克公司 |
掩蔽抗cd3抗体和使用方法
|
WO2016179194A1
(en)
|
2015-05-04 |
2016-11-10 |
Jounce Therapeutics, Inc. |
Lilra3 and method of using the same
|
KR20180015650A
(ko)
|
2015-05-07 |
2018-02-13 |
아게누스 인코포레이티드 |
항-ox40 항체 및 이의 사용 방법
|
US20160346387A1
(en)
|
2015-05-11 |
2016-12-01 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
EP3294770B2
(en)
|
2015-05-12 |
2024-03-20 |
F. Hoffmann-La Roche AG |
Therapeutic and diagnostic methods for cancer
|
WO2016196343A1
(en)
|
2015-05-29 |
2016-12-08 |
Genentech, Inc. |
Humanized anti-ebola virus glycoprotein antibodies and methods of use
|
AU2016270625B2
(en)
|
2015-05-29 |
2022-10-06 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
AU2016271142A1
(en)
|
2015-05-29 |
2017-11-23 |
Genentech, Inc. |
PD-L1 promoter methylation in cancer
|
WO2016196679A1
(en)
|
2015-06-02 |
2016-12-08 |
Genentech, Inc. |
Compositions and methods for using anti-il-34 antibodies to treat neurological diseases
|
WO2016196975A1
(en)
|
2015-06-03 |
2016-12-08 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
MX367312B
(es)
|
2015-06-04 |
2019-08-14 |
Ospedale San Raffaele Srl |
Inhibidor del eje igrbp3/tmem219 y diabetes.
|
EP3302520B1
(en)
|
2015-06-04 |
2020-08-05 |
Ospedale San Raffaele S.r.l. |
Igfbp3 and uses thereof
|
CN107849124B
(zh)
|
2015-06-05 |
2021-09-24 |
基因泰克公司 |
抗tau抗体及使用方法
|
JP2018521019A
(ja)
|
2015-06-08 |
2018-08-02 |
ジェネンテック, インコーポレイテッド |
抗ox40抗体を使用して癌を治療する方法
|
CA2988420A1
(en)
|
2015-06-08 |
2016-12-15 |
Genentech, Inc. |
Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
|
US10017577B2
(en)
|
2015-06-15 |
2018-07-10 |
Genentech, Inc. |
Antibodies and immunoconjugates
|
RU2748943C2
(ru)
|
2015-06-16 |
2021-06-02 |
Дженентек, Инк. |
ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА И АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ ПРОТИВ FcRH5 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック, インコーポレイテッド |
抗cll-1抗体及び使用方法
|
CN107849145B
(zh)
|
2015-06-16 |
2021-10-26 |
基因泰克公司 |
抗cd3抗体及其使用方法
|
JP2018524312A
(ja)
|
2015-06-17 |
2018-08-30 |
ジェネンテック, インコーポレイテッド |
抗her2抗体及び使用方法
|
US10774145B2
(en)
|
2015-06-17 |
2020-09-15 |
Allakos Inc. |
Methods and compositions for treating fibrotic diseases
|
EP3310815A1
(en)
|
2015-06-17 |
2018-04-25 |
F. Hoffmann-La Roche AG |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
HUE057952T2
(hu)
|
2015-06-24 |
2022-06-28 |
Hoffmann La Roche |
Anti-transzferrin receptor antitestek testreszabott affinitással
|
BR112017027736A2
(pt)
|
2015-06-29 |
2018-10-09 |
Genentech Inc |
anticorpo anti-cd20 tipo ii para uso no transplante de órgãos
|
ES2898065T3
(es)
|
2015-06-29 |
2022-03-03 |
Ventana Med Syst Inc |
Materiales y procedimientos para realizar ensayos histoquímicos para proepirregulina y anfirregulina humanas
|
RU2611685C2
(ru)
*
|
2015-07-20 |
2017-02-28 |
Илья Владимирович Духовлинов |
Гуманизированное моноклональное антитело, специфичное к синдекану-1
|
EP4137158A1
(en)
|
2015-08-07 |
2023-02-22 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
EP3341415B1
(en)
|
2015-08-28 |
2021-03-24 |
H. Hoffnabb-La Roche Ag |
Anti-hypusine antibodies and uses thereof
|
CN108699145A
(zh)
|
2015-09-02 |
2018-10-23 |
伊缪泰普有限公司 |
抗lag-3抗体
|
WO2017050729A1
(en)
|
2015-09-22 |
2017-03-30 |
Spring Bioscience Corporation |
Anti-ox40 antibodies and diagnostic uses thereof
|
IL257565B1
(en)
|
2015-09-23 |
2024-04-01 |
Genentech Inc |
Improved variants of anti-VEGF antibodies
|
US11142565B2
(en)
|
2015-09-24 |
2021-10-12 |
Abvitro Llc |
Broadly neutralizing anti-HIV-1 antibodies that bind to an N-glycan epitope on the envelope
|
US10017572B2
(en)
|
2015-09-25 |
2018-07-10 |
Genentech, Inc. |
Anti-tigit antibodies and methods of use
|
US10358497B2
(en)
|
2015-09-29 |
2019-07-23 |
Amgen Inc. |
Methods of treating cardiovascular disease with an ASGR inhibitor
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
UA125962C2
(uk)
|
2015-10-02 |
2022-07-20 |
Ф. Хоффманн-Ля Рош Аг |
Біспецифічна антигензв'язуюча молекула до ox40 та фібробласт-активуючого білка (fap)
|
AR106189A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
|
JP6657392B2
(ja)
|
2015-10-02 |
2020-03-04 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性抗ヒトcd20/ヒトトランスフェリン受容体抗体及び使用方法
|
MA43028B1
(fr)
|
2015-10-02 |
2021-09-30 |
Hoffmann La Roche |
Anticorps bispécifiques pour pd1 et tim3
|
JP2018529747A
(ja)
|
2015-10-06 |
2018-10-11 |
ジェネンテック, インコーポレイテッド |
多発性硬化症を治療するための方法
|
CA2997809A1
(en)
|
2015-10-07 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
JP7074665B2
(ja)
|
2015-10-07 |
2022-05-24 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激tnf受容体に対する四価の二重特異性抗体発明の分野
|
KR20180066236A
(ko)
|
2015-10-22 |
2018-06-18 |
조운스 테라퓨틱스, 인크. |
Icos 발현을 계측하기 위한 유전자 특질
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
WO2017072210A1
(en)
|
2015-10-29 |
2017-05-04 |
F. Hoffmann-La Roche Ag |
Anti-variant fc-region antibodies and methods of use
|
BR112018007703A2
(pt)
|
2015-10-30 |
2018-11-06 |
Genentech Inc |
anticorpos, ácido nucleico isolado, métodos de produção de um anticorpo e de tratamento de um distúrbio, composição farmacêutica, terapia de combinação e uso do anticorpo
|
JP2018534930A
(ja)
|
2015-10-30 |
2018-11-29 |
ジェネンテック, インコーポレイテッド |
抗d因子抗体及びコンジュゲート
|
CA3003878A1
(en)
|
2015-11-03 |
2017-05-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 gp41 and their use
|
WO2017079768A1
(en)
|
2015-11-08 |
2017-05-11 |
Genentech, Inc. |
Methods of screening for multispecific antibodies
|
CN108368174B
(zh)
|
2015-11-23 |
2023-04-14 |
戊瑞治疗有限公司 |
用于癌症治疗的单独fgfr2抑制剂或与免疫刺激剂的组合
|
MX2018005229A
(es)
|
2015-12-09 |
2019-04-29 |
F HoffmannLa Roche Ag |
Anticuerpo anti-cd20 de tipo ii y usos del mismo.
|
PE20240365A1
(es)
|
2015-12-18 |
2024-03-04 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-c5 y metodos de uso
|
WO2017117311A1
(en)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
KR20180097615A
(ko)
|
2016-01-08 |
2018-08-31 |
에프. 호프만-라 로슈 아게 |
Pd-1 축 결합 길항물질 및 항-cea/항-cd3 이중특이성 항체를 사용하는 cea-양성 암의 치료 방법
|
CN108602883A
(zh)
|
2016-01-20 |
2018-09-28 |
基因泰克公司 |
用于阿尔茨海默氏病的高剂量治疗
|
BR112018015259A2
(pt)
*
|
2016-01-27 |
2018-12-18 |
Medimmune Llc |
métodos para preparação de anticorpos com um padrão de glicosilação definido
|
CN109071625A
(zh)
|
2016-02-04 |
2018-12-21 |
柯瑞斯公司 |
平滑化突变体和其使用方法
|
EP3419664A4
(en)
*
|
2016-02-25 |
2019-08-28 |
B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University |
COMPOSITION AND METHOD FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS
|
CN114395624A
(zh)
|
2016-02-29 |
2022-04-26 |
基因泰克公司 |
用于癌症的治疗和诊断方法
|
JP2019515876A
(ja)
|
2016-03-08 |
2019-06-13 |
アカデミア シニカAcademia Sinica |
N−グリカンおよびそのアレイのモジュール合成のための方法
|
CA3016552A1
(en)
|
2016-03-15 |
2017-09-21 |
Genentech, Inc. |
Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodies
|
US20170315132A1
(en)
|
2016-03-25 |
2017-11-02 |
Genentech, Inc. |
Multiplexed total antibody and antibody-conjugated drug quantification assay
|
EP3436477A2
(en)
|
2016-03-29 |
2019-02-06 |
Janssen Biotech, Inc. |
Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
|
AU2017247796A1
(en)
|
2016-04-05 |
2018-09-27 |
Glaxosmithkline Intellectual Property Development Limited |
Inhibition of TGFBeta in immunotherapy
|
US20170319688A1
(en)
|
2016-04-14 |
2017-11-09 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
EP3443120A2
(en)
|
2016-04-15 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
Methods for monitoring and treating cancer
|
WO2017180842A1
(en)
|
2016-04-15 |
2017-10-19 |
Bioatla, Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
KR20190003958A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암의 치료 및 모니터링 방법
|
EP3889175A1
(en)
|
2016-05-02 |
2021-10-06 |
F. Hoffmann-La Roche AG |
The contorsbody - a single chain target binder
|
WO2017192589A1
(en)
|
2016-05-02 |
2017-11-09 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to influenza ha and their use and identification
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
EP3455252B1
(en)
|
2016-05-11 |
2022-02-23 |
F. Hoffmann-La Roche AG |
Modified anti-tenascin antibodies and methods of use
|
CN109071652B
(zh)
|
2016-05-11 |
2022-09-23 |
豪夫迈·罗氏有限公司 |
包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
|
PT3455261T
(pt)
|
2016-05-13 |
2022-11-11 |
Bioatla Llc |
Anticorpos anti-ror2, fragmentos de anticorpo, seus imunoconjugados e suas utilizações
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
JP2019522633A
(ja)
|
2016-05-20 |
2019-08-15 |
ジェネンテック, インコーポレイテッド |
Protac抗体コンジュゲート及び使用方法
|
WO2017205741A1
(en)
|
2016-05-27 |
2017-11-30 |
Genentech, Inc. |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
TW201902512A
(zh)
|
2016-06-02 |
2019-01-16 |
瑞士商赫孚孟拉羅股份公司 |
治療方法
|
EP3475298A1
(en)
|
2016-06-24 |
2019-05-01 |
H. Hoffnabb-La Roche Ag |
Anti-polyubiquitin multispecific antibodies
|
CN109415435B
(zh)
|
2016-07-04 |
2024-01-16 |
豪夫迈·罗氏有限公司 |
新型抗体形式
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
MX2018015721A
(es)
|
2016-07-29 |
2019-05-27 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos biespecificos que exhiben actividad de funcion de cofactor fviii alternativa mejorada.
|
JP7062640B2
(ja)
|
2016-07-29 |
2022-05-06 |
ジュノー セラピューティクス インコーポレイテッド |
抗cd19抗体に対する抗イディオタイプ抗体
|
NL2017270B1
(en)
|
2016-08-02 |
2018-02-09 |
Aduro Biotech Holdings Europe B V |
New anti-hCTLA-4 antibodies
|
CA3026050A1
(en)
|
2016-08-05 |
2018-02-08 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for prophylaxis or treatment of il-8 related diseases
|
WO2018029124A1
(en)
|
2016-08-08 |
2018-02-15 |
F. Hoffmann-La Roche Ag |
Therapeutic and diagnostic methods for cancer
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
EP3507305A1
(en)
|
2016-09-02 |
2019-07-10 |
Dana-Farber Cancer Institute, Inc. |
Composition and methods of treating b cell disorders
|
EP3510046A4
(en)
|
2016-09-07 |
2020-05-06 |
The Regents of the University of California |
ANTIBODIES AGAINST OXIDATION-SPECIFIC EPITOPES
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
WO2018050878A1
(en)
|
2016-09-19 |
2018-03-22 |
F. Hoffmann-La Roche Ag |
Complement factor based affinity chromatography
|
RU2752785C2
(ru)
|
2016-09-23 |
2021-08-04 |
Дженентек, Инк. |
Применение антагонистов il-13 для лечения атопического дерматита
|
JOP20190055A1
(ar)
|
2016-09-26 |
2019-03-24 |
Merck Sharp & Dohme |
أجسام مضادة ضد cd27
|
WO2018064436A1
(en)
|
2016-09-30 |
2018-04-05 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriasis with anti-il23 specific antibody
|
CA3037086A1
(en)
|
2016-10-03 |
2018-04-12 |
Juno Therapeutics, Inc. |
Hpv-specific binding molecules
|
CN110139674B
(zh)
|
2016-10-05 |
2023-05-16 |
豪夫迈·罗氏有限公司 |
制备抗体药物缀合物的方法
|
CN110418851A
(zh)
|
2016-10-06 |
2019-11-05 |
基因泰克公司 |
癌症的治疗和诊断方法
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
US20200023072A1
(en)
|
2016-10-11 |
2020-01-23 |
Medimmune Limited |
Antibody-drug conjugates with immune-mediated therapy agents
|
CN110267678A
(zh)
|
2016-10-29 |
2019-09-20 |
霍夫曼-拉罗奇有限公司 |
抗mic抗体和使用方法
|
EP3535298B1
(en)
|
2016-11-02 |
2021-09-08 |
Jounce Therapeutics, Inc. |
Antibodies to pd-1 and uses thereof
|
KR20190074300A
(ko)
|
2016-11-15 |
2019-06-27 |
제넨테크, 인크. |
항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
|
MA46861A
(fr)
|
2016-11-16 |
2019-09-25 |
Janssen Biotech Inc |
Procédé de traitement du psoriasis avec un anticorps anti-il-23 spécifique
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
KR102532256B1
(ko)
|
2016-11-21 |
2023-05-12 |
쿠레아브 게엠베하 |
항-gp73 항체 및 면역접합체
|
WO2018102746A1
(en)
|
2016-12-02 |
2018-06-07 |
Rigel Pharmaceuticals, Inc. |
Antigen binding molecules to tigit
|
KR20240035636A
(ko)
|
2016-12-07 |
2024-03-15 |
제넨테크, 인크. |
항-타우 항체 및 이의 이용 방법
|
WO2018106781A1
(en)
|
2016-12-07 |
2018-06-14 |
Genentech, Inc |
Anti-tau antibodies and methods of use
|
CN110300599A
(zh)
|
2016-12-07 |
2019-10-01 |
艾吉纳斯公司 |
抗体和其使用方法
|
JP2020511408A
(ja)
|
2016-12-12 |
2020-04-16 |
ジェネンテック, インコーポレイテッド |
抗pd−l1抗体及び抗アンドロゲン薬を使用してがんを治療する方法
|
CA3039430A1
(en)
|
2016-12-19 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted 4-1bb (cd137) agonists
|
BR112019007267A2
(pt)
|
2016-12-20 |
2019-07-09 |
Hoffmann La Roche |
anticorpo biespecífico anti-cd20/anti-cd3, produto farmacêutico, composição farmacêutica que compreende um anticorpo biespecífico anti-cd20/anti-cd3, uso de combinação de anticorpo biespecífico anti-cd20/anti-cd3 e um agonista de 4-1bb e método de tratamento ou retardamento da progressão de câncer em pacientes
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
CA3047070A1
(en)
|
2017-01-03 |
2018-07-12 |
F.Hoffmann-La Roche Ag |
Bispecific antigen binding molecules comprising anti-4-1bb clone 20h4.9
|
WO2018129029A1
(en)
|
2017-01-04 |
2018-07-12 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
US11274157B2
(en)
|
2017-01-12 |
2022-03-15 |
Eureka Therapeutics, Inc. |
Constructs targeting histone H3 peptide/MHC complexes and uses thereof
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
EP3580235B1
(en)
|
2017-02-10 |
2024-05-01 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
MY197534A
(en)
|
2017-02-10 |
2023-06-21 |
Genentech Inc |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
ES2953595T3
(es)
|
2017-03-01 |
2023-11-14 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
MX2019011141A
(es)
|
2017-03-22 |
2019-11-05 |
Genentech Inc |
Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares.
|
TW201836640A
(zh)
|
2017-03-28 |
2018-10-16 |
美商建南德克公司 |
治療神經退化性疾病之方法
|
CN110573528B
(zh)
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
针对共刺激性tnf受体的双特异性抗原结合分子
|
CN110382542B
(zh)
|
2017-03-29 |
2023-06-09 |
豪夫迈·罗氏有限公司 |
针对共刺激性tnf受体的双特异性抗原结合分子
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
MX2019011769A
(es)
|
2017-04-03 |
2019-11-07 |
Hoffmann La Roche |
Anticuerpos que se unen a steap-1.
|
CN110402255B
(zh)
|
2017-04-04 |
2022-12-02 |
豪夫迈·罗氏有限公司 |
新颖的能够特异性结合cd40和fap的双特异性抗原结合分子
|
LT3606954T
(lt)
|
2017-04-05 |
2022-09-26 |
F. Hoffmann-La Roche Ag |
Anti-lag3 antikūnai
|
JP6997212B2
(ja)
|
2017-04-05 |
2022-02-04 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd1及びlag3に特異的に結合する二重特異性抗体
|
CA3058478A1
(en)
|
2017-04-14 |
2018-10-18 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
WO2018195472A1
(en)
|
2017-04-21 |
2018-10-25 |
Genentech, Inc. |
Use of klk5 antagonists for treatment of a disease
|
KR20240067275A
(ko)
|
2017-04-26 |
2024-05-16 |
유레카 쎄라퓨틱스, 인코포레이티드 |
글리피칸 3을 특이적으로 인식하는 구축물 및 그의 용도
|
KR20200003843A
(ko)
|
2017-04-27 |
2020-01-10 |
테사로, 인코포레이티드 |
림프구 활성화 유전자-3 (lag-3)에 대한 항체 작용제 및 그의 용도
|
CN110831628A
(zh)
|
2017-05-05 |
2020-02-21 |
爱乐科斯公司 |
用于治疗过敏性眼病的方法和组合物
|
JP7299842B2
(ja)
|
2017-05-16 |
2023-06-28 |
ファイヴ プライム セラピューティクス インク |
がん治療における化学療法剤と組み合わせた抗fgfr2抗体
|
CN110945028B
(zh)
|
2017-07-10 |
2023-09-08 |
国际药物发展生物技术公司 |
用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤
|
EP3655034A1
(en)
|
2017-07-21 |
2020-05-27 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
CA3071193A1
(en)
|
2017-07-26 |
2019-01-31 |
Forty Seven, Inc. |
Anti-sirp-alpha antibodies and related methods
|
KR20200038305A
(ko)
|
2017-08-25 |
2020-04-10 |
파이브 프라임 테라퓨틱스, 인크. |
B7-h4 항체 및 그의 사용 방법
|
WO2019059411A1
(en)
|
2017-09-20 |
2019-03-28 |
Chugai Seiyaku Kabushiki Kaisha |
DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
|
TW201922780A
(zh)
|
2017-09-25 |
2019-06-16 |
美商健生生物科技公司 |
以抗il12/il23抗體治療狼瘡之安全且有效之方法
|
US11952408B2
(en)
|
2017-10-03 |
2024-04-09 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
US11230601B2
(en)
|
2017-10-10 |
2022-01-25 |
Tilos Therapeutics, Inc. |
Methods of using anti-lap antibodies
|
CA3185107A1
(en)
|
2017-10-12 |
2019-04-18 |
Immunowake Inc. |
Vegfr-antibody light chain fusion protein
|
JP7098725B2
(ja)
|
2017-11-01 |
2022-07-11 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
二重特異性2+1コントースボディ
|
CA3079036A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted ox40 agonists
|
KR20200074997A
(ko)
|
2017-11-01 |
2020-06-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
|
JP2021500902A
(ja)
|
2017-11-01 |
2021-01-14 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
新規tnfファミリーリガンド三量体含有抗原結合分子
|
TW201923089A
(zh)
|
2017-11-06 |
2019-06-16 |
美商建南德克公司 |
癌症之診斷及治療方法
|
TWI830711B
(zh)
|
2017-12-01 |
2024-02-01 |
美商輝瑞大藥廠 |
抗cxcr5抗體及組合物及其用途
|
JP7422659B2
(ja)
|
2017-12-08 |
2024-01-26 |
アルジェニクス ビーブイ |
全身型重症筋無力症治療のためのFcRnアンタゴニストの使用
|
CN112204048A
(zh)
|
2017-12-15 |
2021-01-08 |
朱诺治疗学股份有限公司 |
抗cct5结合分子及其使用方法
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
MA51302A
(fr)
|
2017-12-21 |
2021-03-31 |
Hoffmann La Roche |
Anticorps se liant à hla-a2/wt1
|
US20190211098A1
(en)
|
2017-12-22 |
2019-07-11 |
Genentech, Inc. |
Use of pilra binding agents for treatment of a disease
|
US10723798B2
(en)
|
2017-12-22 |
2020-07-28 |
Jounce Therapeutics, Inc. |
Antibodies to LILRB2
|
JP7369127B2
(ja)
|
2017-12-28 |
2023-10-25 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Tigitに対する単一ドメイン抗体及びその変異体
|
CA3078849A1
(en)
|
2017-12-28 |
2019-07-04 |
Nanjing Legend Biotech Co., Ltd. |
Antibodies and variants thereof against pd-l1
|
WO2019129679A1
(en)
|
2017-12-29 |
2019-07-04 |
F. Hoffmann-La Roche Ag |
Method for improving vegf-receptor blocking selectivity of an anti-vegf antibody
|
WO2019136029A1
(en)
|
2018-01-02 |
2019-07-11 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to ebola virus glycoprotein and their use
|
BR112020013663A2
(pt)
|
2018-01-05 |
2020-12-01 |
Ac Immune Sa |
moléculas de ligação ao tdp-43 dobrado incorretamente
|
EP3508499A1
(en)
|
2018-01-08 |
2019-07-10 |
iOmx Therapeutics AG |
Antibodies targeting, and other modulators of, an immunoglobulin gene associated with resistance against anti-tumour immune responses, and uses thereof
|
SG11202004233UA
(en)
|
2018-01-15 |
2020-06-29 |
Nanjing Legend Biotech Co Ltd |
Single-domain antibodies and variants thereof against pd-1
|
WO2019143636A1
(en)
|
2018-01-16 |
2019-07-25 |
Lakepharma, Inc. |
Bispecific antibody that binds cd3 and another target
|
BR112020015016A2
(pt)
|
2018-01-26 |
2020-12-29 |
Genentech, Inc. |
Composições farmacêuticas, métodos de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana no intestino e de aceleração ou melhora da cicatrização de feridas
|
MA51676A
(fr)
|
2018-01-26 |
2021-05-05 |
Hoffmann La Roche |
Protéines de fusion il-22 fc et procédés d'utilisation
|
US11807663B2
(en)
|
2018-02-01 |
2023-11-07 |
Innovent Biologics (Suzhou) Co., Ltd. |
Fully humanized anti-B cell maturation antigen (BCMA) single-chain antibody and use thereof
|
PE20211116A1
(es)
|
2018-02-08 |
2021-06-23 |
Genentech Inc |
Moleculas biespecificas de union al antigeno y metodos de uso
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
CA3088557C
(en)
|
2018-02-09 |
2024-02-27 |
Genentech, Inc. |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
EP3752530A1
(en)
|
2018-02-14 |
2020-12-23 |
ABBA Therapeutics AG |
Anti-human pd-l2 antibodies
|
EP3755713A1
(en)
|
2018-02-21 |
2020-12-30 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
KR20200123118A
(ko)
|
2018-02-21 |
2020-10-28 |
제넨테크, 인크. |
IL-22 Fc 융합 단백질로 치료를 위한 투약
|
MX2020008736A
(es)
|
2018-02-21 |
2020-12-07 |
Five Prime Therapeutics Inc |
Formulaciones de anticuerpos b7-h4.
|
MX2020008730A
(es)
|
2018-02-21 |
2020-12-07 |
Five Prime Therapeutics Inc |
Regímenes de dosificación de anticuerpo b7-h4.
|
EP3759141A1
(en)
|
2018-02-26 |
2021-01-06 |
F. Hoffmann-La Roche AG |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
CA3091801A1
(en)
|
2018-03-02 |
2019-09-06 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
MX2020009265A
(es)
|
2018-03-05 |
2020-10-01 |
Janssen Biotech Inc |
Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
|
CN111683961A
(zh)
|
2018-03-13 |
2020-09-18 |
豪夫迈·罗氏有限公司 |
4-1bb激动剂与抗cd20抗体的治疗剂组合
|
CN111655731A
(zh)
|
2018-03-13 |
2020-09-11 |
豪夫迈·罗氏有限公司 |
用靶向性4-1bb(cd137)激动剂的组合疗法
|
KR20200130831A
(ko)
|
2018-03-14 |
2020-11-20 |
베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 |
항-클라우딘 18.2 항체
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
KR20200132938A
(ko)
|
2018-03-15 |
2020-11-25 |
추가이 세이야쿠 가부시키가이샤 |
지카 바이러스에 대해 교차-반응성을 갖는 항-뎅기 바이러스 항체 및 사용 방법
|
US20210017283A1
(en)
|
2018-03-21 |
2021-01-21 |
Five Prime Therapeutics, Inc. |
Antibodies Binding to Vista at Acidic pH
|
SG11202009542PA
(en)
|
2018-03-29 |
2020-10-29 |
Genentech Inc |
Modulating lactogenic activity in mammalian cells
|
JP7346790B2
(ja)
|
2018-03-30 |
2023-09-20 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Lag‐3に対する単一ドメイン抗体およびその使用
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
WO2019195486A1
(en)
|
2018-04-05 |
2019-10-10 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
MA52182A
(fr)
|
2018-04-13 |
2021-02-17 |
Hoffmann La Roche |
Molécules de liaison à l'antigène ciblant her2 comprenant 4-1bbl
|
US20190345245A1
(en)
|
2018-05-11 |
2019-11-14 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
SG11202011309SA
(en)
|
2018-05-14 |
2020-12-30 |
Werewolf Therapeutics Inc |
Activatable interleukin 12 polypeptides and methods of use thereof
|
AU2019271148B2
(en)
|
2018-05-14 |
2023-07-06 |
Werewolf Therapeutics, Inc. |
Activatable interleukin-2 polypeptides and methods of use thereof
|
MX2020012418A
(es)
|
2018-05-23 |
2021-04-28 |
Adc Therapeutics Sa |
Adyuvante molecular.
|
AU2019275737A1
(en)
|
2018-06-01 |
2021-01-21 |
Tayu Huaxia Biotech Medical Group Co., Ltd. |
Compositions and uses thereof for treating disease or condition
|
EP3802599B1
(en)
|
2018-06-03 |
2023-12-20 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
WO2019235426A1
(ja)
|
2018-06-04 |
2019-12-12 |
中外製薬株式会社 |
細胞質内での半減期が変化した抗原結合分子
|
CA3103936A1
(en)
|
2018-06-18 |
2019-12-26 |
Eureka Therapeutics, Inc. |
Constructs targeting prostate-specific membrane antigen (psma) and uses thereof
|
CA3103017A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
WO2020007817A1
(en)
|
2018-07-04 |
2020-01-09 |
F. Hoffmann-La Roche Ag |
Novel bispecific agonistic 4-1bb antigen binding molecules
|
TWI819024B
(zh)
|
2018-07-09 |
2023-10-21 |
美商戊瑞治療有限公司 |
結合至ilt4的抗體
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
TW202028235A
(zh)
|
2018-07-11 |
2020-08-01 |
美商戊瑞治療有限公司 |
於酸性ph結合至含免疫球蛋白v域之t細胞活化抑制子(vista)之抗體
|
US20200025776A1
(en)
|
2018-07-18 |
2020-01-23 |
Janssen Biotech, Inc. |
Sustained Response Predictors After Treatment With Anti-IL23 Specific Antibody
|
US20200171146A1
(en)
|
2018-07-18 |
2020-06-04 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
MX2021000745A
(es)
|
2018-07-20 |
2021-03-26 |
Surface Oncology Inc |
Composiciones anti-cd112r y metodos.
|
WO2020027330A1
(ja)
|
2018-08-03 |
2020-02-06 |
中外製薬株式会社 |
互いに連結された2つの抗原結合ドメインを含む抗原結合分子
|
US20200047085A1
(en)
|
2018-08-09 |
2020-02-13 |
Regeneron Pharmaceuticals, Inc. |
Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
|
JP6718560B1
(ja)
|
2018-08-10 |
2020-07-08 |
中外製薬株式会社 |
抗cd137抗原結合分子およびその使用
|
CA3107596A1
(en)
|
2018-08-23 |
2020-02-27 |
Seagen Inc. |
Anti-tigit antibodies
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
MX2021003214A
(es)
|
2018-09-19 |
2021-05-12 |
Genentech Inc |
Metodos terapeuticos y de diagnostico para el cancer de vejiga.
|
EP3853249A4
(en)
|
2018-09-21 |
2022-06-22 |
The University of North Carolina at Chapel Hill |
SYNTHETIC BINDERS TO LIMIT PERMEATION THROUGH MUCUS
|
PL3857230T3
(pl)
|
2018-09-21 |
2023-10-16 |
F. Hoffmann-La Roche Ag |
Sposoby diagnostyczne dla potrójnie ujemnego raka piersi
|
WO2020065532A1
(en)
|
2018-09-24 |
2020-04-02 |
Janssen Biotech, Inc. |
Safe and effective method of treating ulcerative colitis with anti-il12/il23 antibody
|
US20220002370A1
(en)
|
2018-09-27 |
2022-01-06 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
EP3861026A1
(en)
|
2018-10-01 |
2021-08-11 |
F. Hoffmann-La Roche AG |
Bispecific antigen binding molecules comprising anti-fap clone 212
|
JP2022511396A
(ja)
|
2018-10-01 |
2022-01-31 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Cd40への三価結合を伴う二重特異性抗原結合分子
|
EP3632929A1
(en)
|
2018-10-02 |
2020-04-08 |
Ospedale San Raffaele S.r.l. |
Antibodies and uses thereof
|
US20220010020A1
(en)
|
2018-10-05 |
2022-01-13 |
Five Prime Therapeutics, Inc. |
Anti-FGFR2 Antibody Formulations
|
CN113164780A
(zh)
|
2018-10-10 |
2021-07-23 |
泰洛斯治疗公司 |
抗lap抗体变体及其用途
|
CN113166242A
(zh)
|
2018-10-15 |
2021-07-23 |
戊瑞治疗有限公司 |
用于癌症的组合疗法
|
WO2020081493A1
(en)
|
2018-10-16 |
2020-04-23 |
Molecular Templates, Inc. |
Pd-l1 binding proteins
|
KR20210079311A
(ko)
|
2018-10-18 |
2021-06-29 |
제넨테크, 인크. |
육종성 신장암에 대한 진단과 치료 방법
|
EP3873944A1
(en)
|
2018-10-31 |
2021-09-08 |
Bayer Aktiengesellschaft |
Reversal agents for neutralizing the therapeutic activity of anti-fxia antibodies
|
BR112021009373A2
(pt)
|
2018-11-16 |
2021-08-17 |
Memorial Sloan Kettering Cancer Center |
anticorpos para mucina-16 e métodos de uso dos mesmos
|
MX2021005905A
(es)
|
2018-11-20 |
2021-06-23 |
Janssen Biotech Inc |
Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.
|
EP3891185A2
(en)
|
2018-12-05 |
2021-10-13 |
F. Hoffmann-La Roche AG |
Diagnostic methods and compositions for cancer immunotherapy
|
TW202034951A
(zh)
|
2018-12-07 |
2020-10-01 |
日商小野藥品工業股份有限公司 |
免疫抑制劑
|
JP2022513198A
(ja)
|
2018-12-10 |
2022-02-07 |
ジェネンテック, インコーポレイテッド |
Fc含有タンパク質への部位特異的コンジュゲーションのための光架橋性ペプチド
|
WO2020128864A1
(en)
|
2018-12-18 |
2020-06-25 |
Janssen Biotech, Inc. |
Safe and effective method of treating lupus with anti-il12/il23 antibody
|
WO2020132230A2
(en)
|
2018-12-20 |
2020-06-25 |
Genentech, Inc. |
Modified antibody fcs and methods of use
|
US20220089694A1
(en)
|
2018-12-20 |
2022-03-24 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Ebola virus glycoprotein-specific monoclonal antibodies and uses thereof
|
AR117727A1
(es)
|
2018-12-21 |
2021-08-25 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3
|
MY198034A
(en)
|
2018-12-21 |
2023-07-27 |
Hoffmann La Roche |
Tumor-targeted agonistic cd28 antigen binding molecules
|
CN113286822A
(zh)
|
2018-12-21 |
2021-08-20 |
豪夫迈·罗氏有限公司 |
靶向肿瘤的超激动性cd28抗原结合分子
|
EP3898671A1
(en)
|
2018-12-21 |
2021-10-27 |
F. Hoffmann-La Roche AG |
Antibody that binds to vegf and il-1beta and methods of use
|
EP3902832A2
(en)
|
2018-12-26 |
2021-11-03 |
Xilio Development, Inc. |
Anti-ctla4 antibodies and methods of use thereof
|
JP2022515543A
(ja)
|
2018-12-30 |
2022-02-18 |
エフ.ホフマン-ラ ロシュ アーゲー |
抗ウサギcd19抗体および使用方法
|
KR20210116525A
(ko)
|
2019-01-14 |
2021-09-27 |
제넨테크, 인크. |
Pd-1 축 결합 길항제 및 rna 백신으로 암을 치료하는 방법
|
EP3911675A1
(en)
|
2019-01-17 |
2021-11-24 |
Bayer Aktiengesellschaft |
Methods to determine whether a subject is suitable of being treated with an agonist of soluble guanylyl cyclase (sgc)
|
WO2020153467A1
(ja)
|
2019-01-24 |
2020-07-30 |
中外製薬株式会社 |
新規がん抗原及びそれらの抗原に対する抗体
|
CA3123303A1
(en)
|
2019-01-29 |
2020-08-06 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
KR20210133237A
(ko)
|
2019-02-27 |
2021-11-05 |
제넨테크, 인크. |
항-tigit 및 항-cd20 또는 항-cd38 항체로 치료를 위한 투약
|
MX2021010565A
(es)
|
2019-03-08 |
2021-10-13 |
Genentech Inc |
Metodos para detectar y cuantificar proteinas asociadas a la membrana en vesiculas extracelulares.
|
JP2022525145A
(ja)
|
2019-03-14 |
2022-05-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il12/il23抗体組成物を生成するための製造方法
|
KR20210141555A
(ko)
|
2019-03-14 |
2021-11-23 |
제넨테크, 인크. |
Her2xcd3 이중특이적 항체 및 항-her2 mab를 병용한 암의 치료
|
KR20210141583A
(ko)
|
2019-03-18 |
2021-11-23 |
얀센 바이오테크 인코포레이티드 |
항-il-12/il-23 항체를 사용한 소아 대상의 건선 치료 방법
|
GB2589049C
(en)
|
2019-04-11 |
2024-02-21 |
argenx BV |
Anti-IgE antibodies
|
JP7301155B2
(ja)
|
2019-04-12 |
2023-06-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
リポカリンムテインを含む二重特異性抗原結合分子
|
CA3137397A1
(en)
|
2019-04-19 |
2020-10-22 |
Chugai Seiyaku Kabushiki Kaisha |
Chimeric receptor that recognizes engineered site in antibody
|
JP2022529154A
(ja)
|
2019-04-19 |
2022-06-17 |
ジェネンテック, インコーポレイテッド |
抗mertk抗体及びその使用方法
|
JP2022530674A
(ja)
|
2019-05-03 |
2022-06-30 |
ジェネンテック, インコーポレイテッド |
抗pd-l1抗体を用いたがんの処置方法
|
US20220227853A1
(en)
|
2019-05-03 |
2022-07-21 |
The United States Of America,As Represented By The Secretary,Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
CN114450022A
(zh)
|
2019-05-14 |
2022-05-06 |
狼人治疗公司 |
分离部分及其使用方法
|
KR20220007136A
(ko)
|
2019-05-14 |
2022-01-18 |
제넨테크, 인크. |
소포 림프종을 치료하기 위한 항-CD79b 면역접합체의 사용 방법
|
US20230085439A1
(en)
|
2019-05-21 |
2023-03-16 |
University Of Georgia Research Foundation, Inc. |
Antibodies that bind human metapneumovirus fusion protein and their use
|
AU2020278907A1
(en)
|
2019-05-23 |
2022-01-20 |
Ac Immune Sa |
Anti-TDP-43 binding molecules and uses thereof
|
CA3138241A1
(en)
|
2019-05-23 |
2020-11-26 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
|
SG11202112010RA
(en)
|
2019-06-07 |
2021-12-30 |
Argenx Bvba |
PHARMACEUTICAL FORMULATIONS OF FcRn INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION
|
KR20220025848A
(ko)
|
2019-06-26 |
2022-03-03 |
에프. 호프만-라 로슈 아게 |
Cea 및 4-1bbl에 결합하는 항체의 융합
|
EP3990492A1
(en)
|
2019-06-27 |
2022-05-04 |
F. Hoffmann-La Roche AG |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
JP2022539589A
(ja)
|
2019-07-02 |
2022-09-12 |
ザ ユナイテッド ステイツ オブ アメリカ アズ リプリゼンテッド バイ ザ セクレタリー、デパートメント オブ ヘルス アンド ヒューマン サービシーズ |
EGFRvIIIと結合するモノクローナル抗体およびその使用
|
KR20220051164A
(ko)
|
2019-07-05 |
2022-04-26 |
아이오엠엑스 테라퓨틱스 아게 |
Igsf11 (vsig3)의 항체 결합 igc2 및 이의 용도
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
US20220267452A1
(en)
|
2019-07-12 |
2022-08-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-mutation type fgfr3 antibody and use therefor
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
KR20220038415A
(ko)
|
2019-07-26 |
2022-03-28 |
벤더르빌트 유니버시티 |
엔테로바이러스 d68에 대한 인간 모노클로날 항체
|
CA3144524A1
(en)
|
2019-07-31 |
2021-02-04 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
CN114174338A
(zh)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
JP7181438B2
(ja)
|
2019-08-06 |
2022-11-30 |
アプリノイア セラピューティクス リミテッド |
病理学的タウ種に結合する抗体及びその使用
|
AU2020345913A1
(en)
|
2019-09-12 |
2022-02-24 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
CN114423791A
(zh)
|
2019-09-18 |
2022-04-29 |
豪夫迈·罗氏有限公司 |
抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体及使用方法
|
EP4031575A1
(en)
|
2019-09-19 |
2022-07-27 |
Bristol-Myers Squibb Company |
Antibodies binding to vista at acidic ph
|
CR20220149A
(es)
|
2019-09-20 |
2022-05-23 |
Genentech Inc |
Dosis para anticuerpos anti-triptasa
|
AU2020351734A1
(en)
|
2019-09-27 |
2022-04-14 |
Genentech, Inc. |
Dosing for treatment with anti-TIGIT and anti-PD-L1 antagonist antibodies
|
CA3153880A1
(en)
|
2019-10-18 |
2020-06-09 |
Juana Elva HERNANDEZ MONTALVO |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
AU2020378330A1
(en)
|
2019-11-06 |
2022-05-12 |
F. Hoffmann-La Roche Ag |
Diagnostic and therapeutic methods for treatment of hematologic cancers
|
MX2022005718A
(es)
|
2019-11-15 |
2022-07-12 |
Enthera S R L |
Anticuerpos tmem219 y usos terapeuticos de los mismos.
|
EP3822288A1
(en)
|
2019-11-18 |
2021-05-19 |
Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts |
Antibodies targeting, and other modulators of, the cd276 antigen, and uses thereof
|
CA3154017A1
(en)
|
2019-11-21 |
2021-05-27 |
Giovanni AMABILE |
Igfbp3 antibodies and therapeutic uses thereof
|
EP3831849A1
(en)
|
2019-12-02 |
2021-06-09 |
LamKap Bio beta AG |
Bispecific antibodies against ceacam5 and cd47
|
IL293430A
(en)
|
2019-12-06 |
2022-07-01 |
Juno Therapeutics Inc |
Anti-idiotic antibodies to bcma-targeted binding domains and related compositions and methods
|
WO2021113780A1
(en)
|
2019-12-06 |
2021-06-10 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
|
IL293423A
(en)
|
2019-12-13 |
2022-07-01 |
Genentech Inc |
Anti-ly6g6d antibodies and methods of use
|
CA3161390A1
(en)
|
2019-12-18 |
2021-06-24 |
Tina WEINZIERL |
Antibodies binding to hla-a2/mage-a4
|
CN113045655A
(zh)
|
2019-12-27 |
2021-06-29 |
高诚生物医药(香港)有限公司 |
抗ox40抗体及其用途
|
US20230058982A1
(en)
|
2019-12-27 |
2023-02-23 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ctla-4 antibody and use thereof
|
TW202140552A
(zh)
|
2020-01-08 |
2021-11-01 |
比利時商阿根思公司 |
用於治療天皰瘡病症的方法
|
CN114929734A
(zh)
|
2020-01-09 |
2022-08-19 |
豪夫迈·罗氏有限公司 |
新型含有4-1bbl三聚体的抗原结合分子
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
WO2022050954A1
(en)
|
2020-09-04 |
2022-03-10 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
US20230078601A1
(en)
|
2020-01-31 |
2023-03-16 |
The Cleveland Clinic Foundation |
Anti-mullerian hormone receptor 2 antibodies and methods of use
|
CN116650628A
(zh)
|
2020-01-31 |
2023-08-29 |
基因泰克公司 |
用pd-1轴结合拮抗剂和rna疫苗诱导新表位特异性t细胞的方法
|
KR20220140568A
(ko)
|
2020-02-11 |
2022-10-18 |
벤더르빌트 유니버시티 |
중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)에 대한 인간 단일클론 항체
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
CN115087488A
(zh)
|
2020-02-14 |
2022-09-20 |
震动疗法股份有限公司 |
与ccr8结合的抗体和融合蛋白及其用途
|
EP4093762A1
(en)
|
2020-02-20 |
2022-11-30 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Epstein-barr virus monoclonal antibodies and uses thereof
|
EP3868396A1
(en)
|
2020-02-20 |
2021-08-25 |
Enthera S.R.L. |
Inhibitors and uses thereof
|
KR20220145859A
(ko)
|
2020-02-28 |
2022-10-31 |
상하이 헨리우스 바이오테크, 인크. |
항cd137 작제물, 다중 특이적 항체 및 그 용도
|
BR112022016491A2
(pt)
|
2020-02-28 |
2022-10-11 |
Shanghai Henlius Biotech Inc |
Construto anti-cd137 e usos do mesmo
|
US20230126689A1
(en)
|
2020-03-06 |
2023-04-27 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
CR20220461A
(es)
|
2020-03-13 |
2022-10-21 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y usos de estos
|
BR112022018657A2
(pt)
|
2020-03-19 |
2022-11-01 |
Genentech Inc |
Anticorpos, ácido nucleico, célula hospedeira, imunoconjugado, formulação farmacêutica, usos de um anticorpo, métodos de produção de um anticorpo e de tratamento de um indivíduo, métodos para inibir a sinalização de smad e para diagnosticar um indivíduo como tendo ssc e kit
|
WO2021194865A1
(en)
|
2020-03-23 |
2021-09-30 |
Genentech, Inc. |
Method for treating pneumonia, including covid-19 pneumonia, with an il6 antagonist
|
EP4107186A1
(en)
|
2020-03-23 |
2022-12-28 |
Genentech, Inc. |
Tocilizumab and remdesivir combination therapy for covid-19 pneumonia
|
CN115867577A
(zh)
|
2020-03-23 |
2023-03-28 |
基因泰克公司 |
用于预测covid-19肺炎中对il-6拮抗剂反应的生物标志物
|
CR20220489A
(es)
|
2020-03-24 |
2022-10-31 |
Genentech Inc |
Agentes de fijación a tie2 y métodos de uso.
|
CN115315512A
(zh)
|
2020-03-26 |
2022-11-08 |
基因泰克公司 |
具有降低的宿主细胞蛋白质的经修饰的哺乳动物细胞
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
PE20230415A1
(es)
|
2020-03-26 |
2023-03-07 |
Univ Vanderbilt |
ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRA EL CORONAVIRUS 2 DEL SINDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
WO2021207449A1
(en)
|
2020-04-09 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Affinity matured anti-lap antibodies and uses thereof
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
CA3175530A1
(en)
|
2020-04-24 |
2021-10-28 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
AU2021262744A1
(en)
|
2020-04-27 |
2022-10-06 |
The Regents Of The University Of California |
Isoform-independent antibodies to lipoprotein(a)
|
EP4143345A1
(en)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
CN116963782A
(zh)
|
2020-05-03 |
2023-10-27 |
联宁(苏州)生物制药有限公司 |
包含抗trop-2抗体的抗体药物偶联物
|
EP4153312A1
(en)
|
2020-05-17 |
2023-03-29 |
AstraZeneca UK Limited |
Sars-cov-2 antibodies and methods of selecting and using the same
|
WO2021238886A1
(en)
|
2020-05-27 |
2021-12-02 |
Staidson (Beijing) Biopharmaceuticals Co., Ltd. |
Antibodies specifically recognizing nerve growth factor and uses thereof
|
CN116529260A
(zh)
|
2020-06-02 |
2023-08-01 |
当康生物技术有限责任公司 |
抗cd93构建体及其用途
|
JP2023529842A
(ja)
|
2020-06-02 |
2023-07-12 |
ダイナミキュア バイオテクノロジー エルエルシー |
抗cd93構築物およびその使用
|
CN115697489A
(zh)
|
2020-06-08 |
2023-02-03 |
豪夫迈·罗氏有限公司 |
抗hbv抗体及其使用方法
|
CN115698719A
(zh)
|
2020-06-12 |
2023-02-03 |
基因泰克公司 |
用于癌症免疫疗法的方法和组合物
|
MX2022015877A
(es)
|
2020-06-16 |
2023-01-24 |
Genentech Inc |
Metodos y composiciones para tratar cancer de mama triple negativo.
|
JP2023531200A
(ja)
|
2020-06-18 |
2023-07-21 |
ジェネンテック, インコーポレイテッド |
抗tigit抗体及びpd-1軸結合アンタゴニストを用いた治療
|
AU2021291011A1
(en)
|
2020-06-19 |
2023-01-05 |
F. Hoffmann-La Roche Ag |
Antibodies binding to CD3 and CD19
|
MX2022015887A
(es)
|
2020-06-19 |
2023-01-24 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y folr1.
|
CA3176579A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
BR112022025989A2
(pt)
|
2020-06-23 |
2023-01-17 |
Hoffmann La Roche |
Moléculas, um ou mais polinucleotídeos, um ou mais vetores, célula hospedeira, método para produzir uma molécula, composição farmacêutica, uso da molécula e método para tratar uma doença
|
IL299161A
(en)
|
2020-06-24 |
2023-02-01 |
Genentech Inc |
Cell lines resistant to apoptosis
|
JP2023531067A
(ja)
|
2020-06-25 |
2023-07-20 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd3/抗cd28二重特異性抗原結合分子
|
US20240010720A1
(en)
|
2020-07-06 |
2024-01-11 |
Iomx Therapeutics Ag |
Antibodies binding igv of igsf11 (vsig3) and uses thereof
|
MX2023000339A
(es)
|
2020-07-10 |
2023-02-09 |
Hoffmann La Roche |
Anticuerpos que se unen a celulas cancerosas y dirigen radionucleotidos a dichas celulas.
|
KR20230038735A
(ko)
|
2020-07-17 |
2023-03-21 |
제넨테크, 인크. |
항-notch2 항체 및 이용 방법
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
KR20230133832A
(ko)
|
2020-07-29 |
2023-09-19 |
다이내믹큐어 바이오테크놀로지 엘엘씨 |
항-cd93 구축물 및 그의 용도
|
CN116568824A
(zh)
|
2020-08-03 |
2023-08-08 |
基因泰克公司 |
淋巴瘤的诊断和治疗方法
|
EP4192868A1
(en)
|
2020-08-05 |
2023-06-14 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to ror1-targeted binding domains and related compositions and methods
|
KR20230042596A
(ko)
|
2020-08-07 |
2023-03-28 |
제넨테크, 인크. |
Flt3 리간드 융합 단백질 및 이용 방법
|
AU2021325339A1
(en)
|
2020-08-10 |
2023-04-06 |
Astrazeneca Uk Limited |
SARS-CoV-2 antibodies for treatment and prevention of COVID-19
|
US20230322908A1
(en)
|
2020-08-14 |
2023-10-12 |
Ac Immune Sa |
Humanized Anti-TDP-43 Binding Molecules and Uses Thereof
|
EP4204448A2
(en)
|
2020-08-27 |
2023-07-05 |
cureab GmbH |
Anti-golph2 antibodies for macrophage and dendritic cell differentiation
|
WO2022047222A2
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
CN116323663A
(zh)
|
2020-09-04 |
2023-06-23 |
豪夫迈·罗氏有限公司 |
与vegf-a和ang2结合的抗体及其使用方法
|
JP7454106B2
(ja)
|
2020-09-15 |
2024-03-21 |
バイエル・アクチエンゲゼルシヤフト |
新規な抗a2ap抗体およびその使用
|
WO2022060412A1
(en)
|
2020-09-17 |
2022-03-24 |
Genentech, Inc. |
Results of empacta: a randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of tocilizumab in hospitalized patients with covid-19 pneumonia
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US20230372528A1
(en)
|
2020-10-16 |
2023-11-23 |
University Of Georgia Research Foundation, Inc. |
Glycoconjugates
|
TW202233671A
(zh)
|
2020-10-20 |
2022-09-01 |
美商建南德克公司 |
Peg結合抗mertk抗體及其使用方法
|
IL300024A
(en)
|
2020-10-20 |
2023-03-01 |
Hoffmann La Roche |
Combination therapy of PD-1 axis binding antagonists and LRRK2 inhibitors
|
CA3192306A1
(en)
|
2020-10-20 |
2022-04-28 |
Burkhard Ludewig |
Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
|
WO2022093981A1
(en)
|
2020-10-28 |
2022-05-05 |
Genentech, Inc. |
Combination therapy comprising ptpn22 inhibitors and pd-l1 binding antagonists
|
WO2022096536A1
(en)
|
2020-11-03 |
2022-05-12 |
Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts |
Target-cell restricted, costimulatory, bispecific and bivalent anti-cd28 antibodies
|
TW202225191A
(zh)
|
2020-11-04 |
2022-07-01 |
美商建南德克公司 |
抗cd20/抗cd3雙特異性抗體之皮下給藥
|
JP7402381B2
(ja)
|
2020-11-04 |
2023-12-20 |
ジェネンテック, インコーポレイテッド |
抗cd20/抗cd3二重特異性抗体による処置のための投与
|
EP4240493A2
(en)
|
2020-11-04 |
2023-09-13 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies and anti-cd79b antibody drug conjugates
|
WO2022101458A1
(en)
|
2020-11-16 |
2022-05-19 |
F. Hoffmann-La Roche Ag |
Combination therapy with fap-targeted cd40 agonists
|
JP2023551935A
(ja)
|
2020-12-02 |
2023-12-13 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
Il-7結合タンパク質および医学的療法におけるそれらの使用
|
TW202237639A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
鳥苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
TW202237638A
(zh)
|
2020-12-09 |
2022-10-01 |
日商武田藥品工業股份有限公司 |
烏苷酸環化酶c(gcc)抗原結合劑之組成物及其使用方法
|
WO2022132904A1
(en)
|
2020-12-17 |
2022-06-23 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies targeting sars-cov-2
|
CN116829598A
(zh)
|
2021-01-06 |
2023-09-29 |
豪夫迈·罗氏有限公司 |
采用pd1-lag3双特异性抗体和cd20 t细胞双特异性抗体的组合疗法
|
CR20230385A
(es)
|
2021-01-12 |
2023-09-25 |
F Hoffmann La Roche Ag [ |
Anticuerpos split que se unen a células cancerosas y dirigen radionúclidos a dichas células
|
US20240173442A1
(en)
|
2021-01-13 |
2024-05-30 |
Hoffmann-La Roche Inc. |
Combination therapy
|
WO2022162587A1
(en)
|
2021-01-27 |
2022-08-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
WO2022162201A1
(en)
|
2021-01-28 |
2022-08-04 |
Vaccinvent Gmbh |
Method and means for modulating b-cell mediated immune responses
|
CN117120084A
(zh)
|
2021-01-28 |
2023-11-24 |
维肯芬特有限责任公司 |
用于调节b细胞介导的免疫应答的方法和手段
|
WO2022162203A1
(en)
|
2021-01-28 |
2022-08-04 |
Vaccinvent Gmbh |
Method and means for modulating b-cell mediated immune responses
|
JP2024509695A
(ja)
|
2021-02-03 |
2024-03-05 |
ジェネンテック, インコーポレイテッド |
多重特異性結合タンパク質分解プラットフォームおよび使用方法
|
AU2022221297A1
(en)
|
2021-02-09 |
2023-08-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Antibodies targeting the spike protein of coronaviruses
|
AU2022220611A1
(en)
|
2021-02-09 |
2023-08-24 |
University Of Georgia Research Foundation, Inc. |
Human monoclonal antibodies against pneumococcal antigens
|
IL305181A
(en)
|
2021-02-15 |
2023-10-01 |
Takeda Pharmaceuticals Co |
Cell therapy compositions and methods for modulating TGF-B signaling
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
WO2022180145A2
(en)
|
2021-02-26 |
2022-09-01 |
Bayer Aktiengesellschaft |
Inhibitors of il-11 or il-11ra for use in the treatment of abnormal uterine bleeding
|
EP4301467A1
(en)
|
2021-03-01 |
2024-01-10 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
WO2022187272A1
(en)
|
2021-03-01 |
2022-09-09 |
Xilio Development, Inc. |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
WO2022184082A1
(en)
|
2021-03-03 |
2022-09-09 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates comprising an anti-bcma antibody
|
WO2022187863A1
(en)
|
2021-03-05 |
2022-09-09 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
WO2022187591A1
(en)
|
2021-03-05 |
2022-09-09 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
WO2022190033A1
(en)
|
2021-03-12 |
2022-09-15 |
Janssen Biotech, Inc. |
Safe and effective method of treating psoriatic arthritis with anti-il23 specific antibody
|
BR112023018400A2
(pt)
|
2021-03-12 |
2023-12-12 |
Janssen Biotech Inc |
Método para tratamento de pacientes de artrite psoriática com resposta inadequada à terapia de tnf com anticorpo específico anti-il23
|
CN117062839A
(zh)
|
2021-03-12 |
2023-11-14 |
基因泰克公司 |
抗klk7抗体、抗klk5抗体、多特异性抗klk5/klk7抗体和使用方法
|
CA3213599A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
EP4314049A1
(en)
|
2021-03-25 |
2024-02-07 |
Dynamicure Biotechnology LLC |
Anti-igfbp7 constructs and uses thereof
|
KR20230162800A
(ko)
|
2021-03-30 |
2023-11-28 |
바이엘 악티엔게젤샤프트 |
항-sema3a 항체 및 그의 용도
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
TW202305122A
(zh)
|
2021-04-19 |
2023-02-01 |
美商建南德克公司 |
經修飾之哺乳動物細胞
|
WO2022223651A1
(en)
|
2021-04-23 |
2022-10-27 |
F. Hoffmann-La Roche Ag |
Prevention or mitigation of nk cell engaging agent-related adverse effects
|
KR20240005691A
(ko)
|
2021-04-30 |
2024-01-12 |
에프. 호프만-라 로슈 아게 |
항-cd20/항-cd3 이중특이적 항체 및 항-cd79b 항체 약물 접합체를 이용한 병용 치료를 위한 투약
|
WO2022241446A1
(en)
|
2021-05-12 |
2022-11-17 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
EP4337317A1
(en)
|
2021-05-14 |
2024-03-20 |
Genentech, Inc. |
Agonists of trem2
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
CN117396599A
(zh)
|
2021-05-21 |
2024-01-12 |
基因泰克公司 |
用于生产目的重组产物的经修饰的细胞
|
JP2024521187A
(ja)
|
2021-05-28 |
2024-05-28 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
ガンの治療のための組み合わせ療法
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
AR126054A1
(es)
|
2021-06-04 |
2023-09-06 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos anti-ddr2 y usos de estos
|
WO2022258600A1
(en)
|
2021-06-09 |
2022-12-15 |
F. Hoffmann-La Roche Ag |
Combination of a particular braf inhibitor (paradox breaker) and a pd-1 axis binding antagonist for use in the treatment of cancer
|
CN117980333A
(zh)
|
2021-06-11 |
2024-05-03 |
基因泰克公司 |
用st2拮抗剂治疗慢性阻塞性肺疾病的方法
|
WO2022263638A1
(en)
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
WO2022266660A1
(en)
|
2021-06-17 |
2022-12-22 |
Amberstone Biosciences, Inc. |
Anti-cd3 constructs and uses thereof
|
EP4361176A1
(en)
|
2021-06-25 |
2024-05-01 |
Chugai Seiyaku Kabushiki Kaisha |
Use of anti-ctla-4 antibody
|
CA3221833A1
(en)
|
2021-06-25 |
2022-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ctla-4 antibody
|
CN118103397A
(zh)
|
2021-07-08 |
2024-05-28 |
舒泰神(加州)生物科技有限公司 |
特异性识别tnfr2的抗体及其用途
|
EP4367138A1
(en)
|
2021-07-09 |
2024-05-15 |
Janssen Biotech, Inc. |
Manufacturing methods for producing anti-il12/il23 antibody compositions
|
EP4370545A1
(en)
|
2021-07-12 |
2024-05-22 |
Genentech, Inc. |
Structures for reducing antibody-lipase binding
|
CA3224853A1
(en)
|
2021-07-14 |
2023-01-19 |
Gautham GAMPA |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
CN115812082A
(zh)
|
2021-07-14 |
2023-03-17 |
舒泰神(北京)生物制药股份有限公司 |
特异性识别cd40的抗体及其应用
|
CA3219606A1
(en)
|
2021-07-22 |
2023-01-26 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
EP4380980A1
(en)
|
2021-08-03 |
2024-06-12 |
F. Hoffmann-La Roche AG |
Bispecific antibodies and methods of use
|
EP4380604A1
(en)
|
2021-08-05 |
2024-06-12 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
KR20240046524A
(ko)
|
2021-08-07 |
2024-04-09 |
제넨테크, 인크. |
미만성 거대 b-세포 림프종을 치료하기 위해 항-cd79b 면역접합체를 사용하는 방법
|
EP4384553A1
(en)
|
2021-08-13 |
2024-06-19 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
WO2023017483A1
(en)
|
2021-08-13 |
2023-02-16 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for ccr2-expressing cells
|
AU2022327859A1
(en)
|
2021-08-13 |
2024-02-22 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras
|
CN117858905A
(zh)
|
2021-08-19 |
2024-04-09 |
豪夫迈·罗氏有限公司 |
多价抗变体fc区抗体及使用方法
|
AU2022332285A1
(en)
|
2021-08-23 |
2024-02-15 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
TW202328177A
(zh)
|
2021-08-27 |
2023-07-16 |
美商建南德克公司 |
治療tau病理學之方法
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
AU2022339819A1
(en)
|
2021-09-03 |
2024-04-11 |
Go Therapeutics, Inc. |
Anti-glyco-lamp1 antibodies and their uses
|
WO2023034569A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
CA3232223A1
(en)
|
2021-09-17 |
2023-03-23 |
Ying Fu |
Synthetic humanized llama nanobody library and use thereof to identify sars-cov-2 neutralizing antibodies
|
TW202321308A
(zh)
|
2021-09-30 |
2023-06-01 |
美商建南德克公司 |
使用抗tigit抗體、抗cd38抗體及pd—1軸結合拮抗劑治療血液癌症的方法
|
CA3233953A1
(en)
|
2021-10-05 |
2023-04-13 |
Matthew Bruce |
Combination therapies for treating cancer
|
TW202323810A
(zh)
|
2021-10-08 |
2023-06-16 |
日商中外製藥股份有限公司 |
預填充式注射器製劑的調製方法
|
AU2022374890A1
(en)
|
2021-10-29 |
2024-06-13 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
AU2022379952A1
(en)
|
2021-11-05 |
2024-05-16 |
American Diagnostics & Therapy, Llc (Adxrx) |
Monoclonal antibodies against carcinoembryonic antigens, and their uses
|
TW202342095A
(zh)
|
2021-11-05 |
2023-11-01 |
英商阿斯特捷利康英國股份有限公司 |
用於治療和預防covid—19之組成物
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
US20230151087A1
(en)
|
2021-11-15 |
2023-05-18 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
TW202337494A
(zh)
|
2021-11-16 |
2023-10-01 |
美商建南德克公司 |
用莫蘇妥珠單抗治療全身性紅斑狼瘡(sle)之方法及組成物
|
WO2023088959A1
(en)
|
2021-11-16 |
2023-05-25 |
Ac Immune Sa |
Novel molecules for therapy and diagnosis
|
US20230159633A1
(en)
|
2021-11-23 |
2023-05-25 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
WO2023094569A1
(en)
|
2021-11-26 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
WO2023109900A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies, multispecific antibodies and methods of use
|
WO2023109901A1
(en)
|
2021-12-17 |
2023-06-22 |
Shanghai Henlius Biotech, Inc. |
Anti-ox40 antibodies and methods of use
|
TW202340248A
(zh)
|
2021-12-20 |
2023-10-16 |
瑞士商赫孚孟拉羅股份公司 |
促效性ltbr抗體及包含其之雙特異性抗體
|
WO2023131901A1
(en)
|
2022-01-07 |
2023-07-13 |
Johnson & Johnson Enterprise Innovation Inc. |
Materials and methods of il-1beta binding proteins
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
WO2023154824A1
(en)
|
2022-02-10 |
2023-08-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Human monoclonal antibodies that broadly target coronaviruses
|
TW202342519A
(zh)
|
2022-02-16 |
2023-11-01 |
瑞士商Ac 免疫有限公司 |
人源化抗tdp-43結合分子及其用途
|
WO2023159182A1
(en)
|
2022-02-18 |
2023-08-24 |
Rakuten Medical, Inc. |
Anti-programmed death-ligand 1 (pd-l1) antibody molecules, encoding polynucleotides, and methods of use
|
WO2023161874A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for c-c chemokine receptor 2-expressing cells
|
WO2023161875A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for prostate specific membrane antigen-expressing cells
|
WO2023161881A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for ccr2-expressing cells
|
WO2023161877A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for integrin avb6-expressing cells
|
WO2023161879A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for fibroblast activation protein-expressing cells
|
WO2023161878A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for folate receptor-expressing cells
|
WO2023161876A1
(en)
|
2022-02-25 |
2023-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Cytotoxicity targeting chimeras for cxcr3-expressing cells
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
WO2023180353A1
(en)
|
2022-03-23 |
2023-09-28 |
F. Hoffmann-La Roche Ag |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023192827A1
(en)
|
2022-03-26 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Bispecific antibodies to hiv-1 env and their use
|
WO2023192881A1
(en)
|
2022-03-28 |
2023-10-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
US20230312703A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of Treating Psoriasis with IL-23 Specific Antibody
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023194565A1
(en)
|
2022-04-08 |
2023-10-12 |
Ac Immune Sa |
Anti-tdp-43 binding molecules
|
JP2024517042A
(ja)
|
2022-04-13 |
2024-04-19 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗cd20/抗cd3二重特異性抗体の薬学的組成物及び使用方法
|
TW202408562A
(zh)
|
2022-04-13 |
2024-03-01 |
美商建南德克公司 |
治療性蛋白質之醫藥組成物及使用方法
|
WO2023203177A1
(en)
|
2022-04-20 |
2023-10-26 |
Kantonsspital St. Gallen |
Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
|
US20230348604A1
(en)
|
2022-04-29 |
2023-11-02 |
23Andme, Inc. |
Antigen binding proteins
|
WO2023209177A1
(en)
|
2022-04-29 |
2023-11-02 |
Astrazeneca Uk Limited |
Sars-cov-2 antibodies and methods of using the same
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
TW202402810A
(zh)
|
2022-05-11 |
2024-01-16 |
瑞士商赫孚孟拉羅股份公司 |
與vegf—a及il6結合之抗體及其使用方法
|
WO2023223265A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for evaluating and treating psoriatic arthritis with il23 antibody
|
WO2023227641A1
(en)
|
2022-05-27 |
2023-11-30 |
Glaxosmithkline Intellectual Property Development Limited |
Use of tnf-alpha binding proteins and il-7 binding proteins in medical treatment
|
WO2023235699A1
(en)
|
2022-05-31 |
2023-12-07 |
Jounce Therapeutics, Inc. |
Antibodies to lilrb4 and uses thereof
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
WO2023237706A2
(en)
|
2022-06-08 |
2023-12-14 |
Institute For Research In Biomedicine (Irb) |
Cross-specific antibodies, uses and methods for discovery thereof
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020407A1
(en)
|
2022-07-19 |
2024-01-25 |
Staidson Biopharma Inc. |
Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US20240132622A1
(en)
|
2022-07-22 |
2024-04-25 |
Bristol-Myers Squibb Company |
Antibodies Binding to Human PAD4 and Uses Thereof
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024030829A1
(en)
|
2022-08-01 |
2024-02-08 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Monoclonal antibodies that bind to the underside of influenza viral neuraminidase
|
WO2024028731A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Transferrin receptor binding proteins for treating brain tumors
|
WO2024028732A1
(en)
|
2022-08-05 |
2024-02-08 |
Janssen Biotech, Inc. |
Cd98 binding constructs for treating brain tumors
|
WO2024042112A1
(en)
|
2022-08-25 |
2024-02-29 |
Glaxosmithkline Intellectual Property Development Limited |
Antigen binding proteins and uses thereof
|
WO2024044779A2
(en)
|
2022-08-26 |
2024-02-29 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3)
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024054929A1
(en)
|
2022-09-07 |
2024-03-14 |
Dynamicure Biotechnology Llc |
Anti-vista constructs and uses thereof
|
WO2024054822A1
(en)
|
2022-09-07 |
2024-03-14 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Engineered sars-cov-2 antibodies with increased neutralization breadth
|
WO2024064826A1
(en)
|
2022-09-22 |
2024-03-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
WO2024077239A1
(en)
|
2022-10-07 |
2024-04-11 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|
WO2024091991A1
(en)
|
2022-10-25 |
2024-05-02 |
Genentech, Inc. |
Therapeutic and diagnostic methods for multiple myeloma
|
US20240165227A1
(en)
|
2022-11-04 |
2024-05-23 |
Gilead Sciences, Inc. |
Anticancer therapies using anti-ccr8 antibody, chemo and immunotherapy combinations
|
WO2024102734A1
(en)
|
2022-11-08 |
2024-05-16 |
Genentech, Inc. |
Compositions and methods of treating childhood onset idiopathic nephrotic syndrome
|
WO2024100200A1
(en)
|
2022-11-09 |
2024-05-16 |
Cis Pharma Ag |
Anti-l1-cam antibodies and their uses for diagnostic and therapeutic applications
|
WO2024100170A1
(en)
|
2022-11-11 |
2024-05-16 |
F. Hoffmann-La Roche Ag |
Antibodies binding to hla-a*02/foxp3
|
WO2024108053A1
(en)
|
2022-11-17 |
2024-05-23 |
Sanofi |
Ceacam5 antibody-drug conjugates and methods of use thereof
|
WO2024110898A1
(en)
|
2022-11-22 |
2024-05-30 |
Janssen Biotech, Inc. |
Method of treating ulcerative colitis with anti-il23 specific antibody
|